Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer Authors: Shan Liu, Xingda Zhang, Wenzheng Wang, Xue Li, Xue Sun, Yuqian Zhao, Qi Wang, Yingpu Li, Fangjie Hu, He Ren Published: 2024 ABSTRACT AbstractMetabolic alterations, a hallmark of cancer, enable tumor cells to adapt to their environment by modulating glucose, lipid, and amino acid metabolism, which fuels rapid growth and contributes to treatment resistance. In primary breast cancer, metabolic shifts such as the Warburg effect and enhanced lipid synthesis are closely linked to chemotherapy failure. Similarly, metastatic lesions often display distinct metabolic profiles that not only sustain tumor growth but also confer resistance to targeted therapies and immunotherapies. The review emphasizes two major aspects: the mechanisms driving metabolic resistance in both primary and metastatic breast cancer, and how the unique metabolic environments in metastatic sites further complicate treatment. By targeting distinct metabolic vulnerabilities at both the primary and metastatic stages, new strategies could improve the efficacy of existing therapies and provide better outcomes for breast cancer patients.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12943-024-02165-x. Introduction Breast cancer is the most commonly diagnosed malignancy among women worldwide and one of the leading causes of female mortality [1]. Based on the expression levels of hormone receptors (HR), human epidermal growth factor receptor 2 (HER2), and Ki-67, breast cancer can be classified into four molecular subtypes: HR-positive/HER2-negative, HR-positive/HER2-positive, HR-negative/HER2-positive, and triple-negative breast cancer (TNBC) [2]. These subtypes exhibit distinct clinical features, biological behaviors, and responses to treatment. Despite advancements in surgery, radiotherapy, chemotherapy, and targeted therapies, significant challenges remain in breast cancer treatment, particularly with drug resistance. Resistance not only limits therapeutic efficacy but also promotes tumor recurrence and metastasis, increasing the risk of mortality. Therefore, understanding the molecular mechanisms of drug resistance and identifying effective methods to predict and reverse it is crucial for improving treatment outcomes and patient survival. Metabolic reprogramming refers to the adjustment of cellular metabolic pathways in response to specific physiological or pathological conditions, enabling cells to adapt to environmental changes and support growth and survival [3]. The tumor microenvironment (TME) is a complex system comprising tumor cells, immune cells, vascular cells, stromal cells, and the extracellular matrix [4]. Within the TME, tumor cells interact with surrounding non-tumor cells through metabolic reprogramming, creating a network that supports tumor progression. These metabolic alterations not only promote tumor cell proliferation and survival but also regulate immune function, foster angiogenesis, and modify the properties of the extracellular matrix [5]. Even in the presence of oxygen, tumor cells preferentially rely on glycolysis over oxidative phosphorylation (OXPHOS), a phenomenon known as the “Warburg effect.” [6] During this process, tumor cells release metabolic byproducts such as lactate and growth factors, influencing cell signaling, modulating immune function, and further promoting tumor growth. Immune cells within the TME also undergo metabolic reprogramming to cope with nutrient-deprived conditions. For instance, T cells and macrophages may increase fatty acid oxidation(FAO) to meet their energy demands [7]. Additionally, metabolic reprogramming in immune cells is closely related to their antitumor or immunosuppressive functions. In the immunosuppressive TME, immune cells often exhibit a tolerant phenotype, accompanied by metabolic adaptations like enhanced glycolysis or OXPHOS [8]. Breast cancer progression involves the formation of the primary tumor and metastasis to distant organs. The molecular characteristics, gene expression, and biological behavior between primary and metastatic sites differ, making the complexity of breast cancer and its therapeutic challenges more evident. The primary tumor is influenced by the mammary tissue microenvironment, while metastatic sites, such as bone or liver metastases, exist in distinct tissue environments. These changes involve variations in extracellular matrix components, oxygen and nutrient supply, immune responses, and intercellular communication [8, 9]. Metabolic reprogramming is a key mechanism through which tumor cells adapt to these changes, with distinct metabolic profiles observed between primary and metastatic sites. Metabolic dysregulation, such as increased glycolysis, TCA cycle activity, glutamine metabolism, and fatty acid biosynthesis, is closely linked to breast cancer progression [10]. In recent years, accumulating evidence has shown that metabolic reprogramming is closely associated with tumor development, progression, and drug resistance. By altering metabolic pathways, tumor cells can reduce drug efficacy and promote resistance. These metabolic adaptations not only enhance the tumor cells’ resilience but also alter the microenvironment (e.g., pH) and metabolic pathways, reducing drug accumulation or accelerating its degradation, ultimately leading to treatment failure [11]. Addressing this challenge requires precise targeting of resistance-related metabolic pathways, especially in the context of different breast cancer subtypes and therapeutic regimens. This review aims to explore the impact of metabolic reprogramming on drug resistance in breast cancer, with a particular focus on metabolic changes in primary and metastatic sites, and how these alterations contribute to resistance development through various molecular mechanisms. Additionally, we will discuss the potential applications of metabolic reprogramming in predicting and reversing drug resistance, offering new strategies and insights for breast cancer treatment. Metabolic reprogramming on therapeutic resistance in In-Situ breast cancer Tumor cell metabolic reprogramming on drug resistance Metabolic reprogramming, also known as metabolic remodeling, is primarily manifested by abnormalities in glucose, glutamine, and lipid metabolism [12], with changes in glucose metabolism being the most prominent in malignant tumor cells (Table 1). Tumor cells alter nutrient acquisition and metabolic pathways to meet their energy demands, biosynthesis needs, and maintenance of redox balance, thereby achieving rapid proliferation. Numerous studies have highlighted differences in metabolic characteristics between breast cancer and normal breast tissue. Various metabolic pathways, such as glycolysis, the TCA cycle, nucleotide metabolism, lipid metabolism, and amino acid metabolism, undergo significant alterations [13–15]. From a metabolic perspective, there is considerable heterogeneity among different subtypes of breast cancer cells [16]. Tumor cells often change their metabolic pathways for survival during treatment, and many studies indicate a close relationship between tumor metabolism and drug resistance (Fig. 1). Therefore, targeting tumor metabolic reprogramming holds promise for overcoming drug resistance and improving the effectiveness of treatments. Table 1Metabolic reprogramming in breast cancerDefinition:Metabolic reprogramming refers to the adaptive alterations in cellular metabolic pathways in response to specific physiological or pathological conditions, enabling cancer cells to support rapid proliferation and survival. This process is particularly pronounced in breast cancer, where metabolic changes play a crucial role in tumor progression and resistance to therapy.Key Features: Glucose Metabolism • Tumor cells exhibit the Warburg effect, prioritizing aerobic glycolysis over oxidative phosphorylation even in the presence of oxygen. This metabolic shift allows cancer cells to produce energy rapidly, although less efficiently than oxidative phosphorylation, to support their rapid proliferation. • The increased influx of glucose into cancer cells is facilitated through a coordinated regulation of metabolic enzymes and pyruvate consumption. Lipid Metabolism • Enhanced fatty acid synthesis and oxidation meet the increased demand for membrane lipids and energy during rapid proliferation of breast cancer cells. • Alterations in lipid metabolism, including changes in fatty acid, phospholipid, eicosanoid, and sphingolipid metabolism, are prominent features of breast cancer. Amino Acid Metabolism • Glutamine metabolism is particularly active in breast cancer cells, providing energy and biosynthetic precursors such as nitrogen, carbon, and fatty acids. • Other nonessential amino acids, such as serine, glycine, cysteine, and arginine-proline, also play important roles in breast cancer metabolism by serving as precursors for the biosynthesis of nucleotides, lipids, and other macromolecules. Metabolic reprogramming in breast cancer Metabolic Reprogramming and Drug Resistance in Breast Cancer. Metabolic reprogramming drives drug resistance in breast cancer cells. Glycolysis converts glucose into lactate, which is exported by MCTs, creating a barrier that limits drug penetration. Pyruvate enters the TCA cycle in the mitochondria, producing energy molecules like NADH and FADH2 that support cell survival. Amino acid metabolism, particularly involving glutamine and glutamate, supplies crucial intermediates for cellular functions. Lipid metabolism, regulated by the mTOR signaling pathway, influences fatty acid oxidation and maintains energy homeostasis. These metabolic adaptations enable breast cancer cells to withstand therapeutic stress, promoting drug resistance Glucose metabolism Warburg effect and aerobic glycolysis The Warburg effect is common in tumors and has been identified as one of the ten characteristics of tumors [17]. At the molecular level, glucose is transported into tumor cells by glucose transporters (GLUT) and converted into pyruvate through a series of glycolytic enzymes. Pyruvate is then catalyzed into lactate-by-lactate dehydrogenase and transported out of the cell by monocarboxylate transporters(MCTs), completing massive glucose consumption and lactate secretion [18]. Increasing evidence suggests that the Warburg effect may influence the efficacy of anti-tumor drugs [19–22]. Previous studies have shown that in some cell lines, upregulation of aerobic glycolysis can lead to drug resistance. For example, gemcitabine in the treatment of pancreatic cancer can induce metabolic reprogramming, reduce mitochondrial oxidation up-regulate aerobic glycolysis, and promote the stem cell-like behavior of tumor cells, causing chemotherapy resistance of pancreatic cancer, which is one of the reasons for the poor prognosis of pancreatic cancer [23]. This indicates that tumor resistance may be related to the Warburg effect [24–26]. The Warburg effect results in higher glucose consumption compared to normal cells [27]. Additionally, many tumors can perform glycolysis even under aerobic conditions [28]. Besides providing energy, glycolytic intermediates play key roles in macromolecule biosynthesis, conferring growth advantages to tumor cells under nutrient-deprived conditions, enhancing tumor invasiveness, and leading to drug resistance. Targeting tumor cell aerobic glycolysis is a promising therapeutic strategy. For instance, glycolysis inhibitors can increase tumor cell sensitivity to chemotherapy drugs. Studies have shown that combining glycolysis inhibitors with chemotherapy drugs enhances the treatment effect on liver cancer cells compared to chemotherapy alone [29]. Several therapeutic targets in tumor glycolysis have been identified, including key enzymes and important transporters in glucose uptake and catabolism. In glucose uptake, the GLUT family plays a crucial role. GLUT1, the most widely distributed subtype in tissues, is overexpressed in malignancies such as breast cancer [30]. Studies have shown that using GLUT1 inhibitors to treat lung cancer cells results in downregulated GLUT1 expression and reduced glucose uptake [31, 32]. This synergistically inhibits lung cancer cell growth and proliferation when combined with chemotherapy drugs like cisplatin and paclitaxel. Inhibiting GLUT activity can also increase tumor cell sensitivity to chemotherapy, highlighting the importance of GLUT proteins in tumor resistance. In glucose catabolism, key enzymes in the aerobic glycolysis pathway, such as hexokinase (HK), phosphofructokinase-1 (PFK1), and pyruvate kinase (PK), are associated with promoting tumor cell drug-resistant phenotypes. HK, the first key enzyme in the glycolytic pathway, catalyzes the conversion of glucose to glucose-6-phosphate. Among the known isoforms, HK2 is highly overexpressed in tumor tissues and extensively studied in tumors [33]. Studies have shown high HK2 expression levels in primary breast cancer [34]. Knocking down HK2 significantly inhibits the expression of major phenotypes in breast cancer cells in vitro and vivo [35]. 2-deoxy-D-glucose (2-DG), an HK2 inhibitor, competes with glucose for hexokinase binding, inhibiting glycolysis. Clinical studies have used 2-DG as an adjunctive therapy in various cancers such as breast cancer, prostate cancer, ovarian cancer, lung cancer, and glioma [36–38]. 2-DG has chemosensitizing effects, enhancing chemotherapy efficacy. Research has shown that combining 2-DG with chemotherapy drugs like doxorubicin and paclitaxel significantly reduces tumor growth rates and extends survival in non-small cell lung cancer mouse models, suggesting that targeting HK can counteract tumor cell drug resistance [39]. Although theoretically attractive due to their potential to selectively starve cancer cells of energy by blocking their primary metabolic pathway, strategies targeting the inhibition of glycolysis have generally failed in clinical trials involving current glycolysis inhibitors (including 2-DG and HK inhibitors). To date, glycolysis inhibitors are known to be non-selective compounds, affecting both cancer and normal cells extensively [33, 40]. Moreover, the metabolic effects of 2-DG can lead to energy metabolism imbalance, such as reduced ATP production through interference with glucose uptake and utilization. This ultimately impairs normal cellular functions. These include inhibiting cell growth, reducing responsiveness to external stimuli, and potentially inducing apoptosis [41–43]. This energy imbalance facilitates metabolic reprogramming, allowing cells to adapt to stress, thereby increasing drug tolerance and ultimately diminishing therapeutic efficacy [24]. A clinical study indicated that 40% of patients receiving 2-DG treatment experienced severe hypoglycemic reactions, which not only complicated treatment but also significantly reduced patient tolerance [37]. Measures such as adjusting the dosage or co-administering glucose have been attempted to manage these hypoglycemic reactions, but they add complexity to the treatment regimen. Additionally, 2-DG and HK2 inhibitors have been observed to impact high-energy-demand organs, including causing metabolic disturbances and myocardial dysfunction in the heart and mitochondrial dysfunction in the brain, leading to cognitive impairment in animal studies [33, 44]. Long-term HK2 inhibitor use has also been associated with muscle weakness and neurotoxicity, with 25% of patients reporting persistent muscle weakness and neuropathy [45]. In addition to toxicity, long-term use of 2-DG and HK2 inhibitors may also lead to metabolic reprogramming, enabling cancer cells to evade drug effects and enhance resistance. Mechanisms of metabolic reprogramming include upregulation of alternative metabolic pathways, such as increased fatty acid oxidation and glutamine metabolism, which satisfy energy requirements and circumvent glycolytic inhibition [46, 47]. For instance, studies have shown that cells can upregulate phosphatases like Dog2 to detoxify 2-DG, reducing its inhibitory effects on glycolysis and allowing cells to restore normal metabolism, which not only limits therapeutic efficacy but may also lead to tumor recurrence [48]. Given these side effects and resistance issues, future research should focus on developing more precise targeted therapeutic strategies, such as nanoparticle-based drug delivery systems, CAR T-cell therapy, or bispecific antibodies. Targeted delivery of therapeutic compounds to immune cells can enhance antitumor immunity, as seen with PD-1-targeted nanoparticles that effectively deliver immunotherapies to tumor-infiltrating lymphocytes [49]. Future strategies may include combining metabolic inhibitors with more precise cancer-targeting technologies, such as CRISPR-Cas9 gene editing, or using synergistic drugs (e.g., PI3K inhibitors) to lower the required dosage and thereby minimize side effects [50, 51]. These strategies underscore the importance of developing next-generation glycolysis inhibitors that can specifically target cancer cells with minimal impact on normal tissues. In conclusion, treatment strategies targeting metabolic pathways (e.g., 2-DG and HK2 inhibitors) hold significant promise due to their potential to disrupt cancer cell metabolism. However, their side effects and resistance issues remain major obstacles to clinical application. Therefore, future research should focus on developing highly selective, low-toxicity drugs and combining multiple therapeutic strategies to optimize overall treatment outcomes. PFK1, the second key enzyme in the glycolytic pathway, converts fructose-6-phosphate(F6P) to fructose-1,6-bisphosphate. Studies have shown increased PFK1 protein expression and activity in cancer tissues compared to normal or adjacent tissues [52]. PFK1 activity is regulated by phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3), which catalyzes the production of fructose-2,6-bisphosphate from (F6P). Fructose-2,6-bisphosphate is an allosteric activator of PFK1, significantly increasing its catalytic activity, making PFKFB3 a key regulator of glycolysis and an important therapeutic target in tumors [53]. PFKFB3 is overexpressed in various cancers, including breast cancer, colon cancer, nasopharyngeal carcinoma, pancreatic cancer, and gastric cancer, and is associated with lymph node metastasis and survival [54]. Inhibitors such as PFK158 and PFK15 have shown synergistic effects with targeted and chemotherapy drugs [55–57]. PK, the third key enzyme in the glycolytic process, converts phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP. PK has four isoenzymes: M1, M2, L, and R. PKM2 is highly expressed in tumor tissues [58]. High PKM2 expression in breast cancer patients is associated with poor survival and lymph node metastasis [59]. PKM2 activity reduction can help overcome hypoxia-induced drug resistance in tumor cells, with its inhibitor TLN-232 effectively reducing drug resistance [60]. Inhibiting PKM2 increases tumor cell sensitivity to chemotherapy drugs like cisplatin, reversing resistance [61, 62]. Lactic acid dehydrogenase (LDH), catalyzing the final step of glycolysis, converts pyruvate to lactate, playing a crucial role in tumor cell metabolism. LDH isoenzymes are encoded by three genes (LDHA, LDHB, and LDHC), with LDHA responsible for converting pyruvate to lactate and LDHB converting lactate to pyruvate. Tumor cells primarily express LDHA, which promotes glycolysis and remodels the TME by increasing lactate production, inhibiting the immune system, and facilitating immune escape [63]. LDHA is a promising therapeutic target. In prostate cancer, the selective LDHA inhibitor FX-11 effectively inhibits glycolysis and tumor cell growth as a single agent [64]. Studies have shown lactate can activate survival signaling pathways under hypoxia. Tumor-derived lactate reduces the immune response against tumor cells [65]. Previous research indicated that lactate dehydrogenase inhibitors significantly improve resistance in breast cancer patients resistant to paclitaxel and trastuzumab [66, 67]. Machilin A inhibits lactate dehydrogenase, reducing lactate production and inhibiting cancer progression [68]. TCA cycle and OXPHOS Although tumor cells rely more on glycolysis, studies have shown that tumor cells must reduce proliferation and shift to OXPHOS after chemotherapy drug treatment. OXPHOS, the coupling reaction where organic matter oxidizes to release energy, synthesizes ATP from ADP and inorganic phosphate through the respiratory chain [69]. The TCA cycle (also known as the citric acid cycle) involves a series of mitochondrial reactions where acetyl-CoA enters the cycle, generating carbon dioxide, reduced coenzymes NADH and FADH2, and a small amount of ATP. These reduced coenzymes transfer electrons to the electron transport chain, producing large amounts of ATP through OXPHOS. Studies have shown tumor cells can rely on OXPHOS for a drug-resistant phenotype [70, 71]. For example, the mitochondrial respiratory chain complex I inhibitor metformin can reverse cisplatin resistance in ovarian cancer cells, reducing tumor cell growth and promoting apoptosis [72]. The complex I-specific inhibitor rotenone inhibits mitochondrial respiration in HL-60 leukemia cells, significantly reducing sensitivity to antitumor drugs like cytarabine and paclitaxel compared to parent cells [24]. Pentose phosphate pathway The pentose phosphate pathway (PPP), also known as the phosphogluconate pathway, is a glucose oxidation pathway essential for synthesizing pentose phosphates and ribonucleotides and is a primary source of NADPH. This pathway plays a critical role in helping glycolysis-preferred tumor cells meet their anabolic needs and resist oxidative stress. Oxidative stress, ionizing radiation, and chemotherapy can elevate ROS levels, with tumor cells increasing PPP activity to counter ROS-induced apoptosis. PPP is more active in most resistant tumors compared to drug-sensitive ones. For example, under vincristine induction, resistant human T-lymphoblastoid cells show elevated G6PD activity and increased GSH levels compared to sensitive cells [73]. Previous research indicated PPP’s crucial role in non-drug-induced resistant cell models [74]. Upregulation of PPP activity and GSH levels in K-ras mutated lung and pancreatic cancers enhances chemotherapy resistance and growth advantage. Thus, combining PPP inhibitors with chemoradiotherapy can enhance treatment efficacy. In vitro studies have shown that the non-competitive G6PD inhibitor dehydroepiandrosterone significantly inhibits PPP activity and NADPH production, enhancing the therapeutic effect of paclitaxel on MDA-MB-231 breast cancer cells [75]. Lipid metabolism Compared to glucose metabolism, lipid metabolism in tumor cells has received relatively less attention. However, recent foundational clinical and epidemiological studies indicate that lipid metabolism disorders may be significant factors in cancer occurrence and development [76], with lipid metabolism playing an essential role in tumor growth. Tumor cells can acquire fatty acids from various intra- and extracellular sources, with altered fatty acid metabolism being a hallmark of tumor occurrence and metastasis [77]. Fatty acid metabolism includes de novo synthesis, oxidation, desaturation, and elongation of fatty acids to different saturation levels and chain lengths. Key enzymes in fatty acid metabolism, such as ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), carnitine palmitoyltransferase (CPT), and different chain-length acyl-CoA dehydrogenases (ACADS, ACADM, ACADL, ACADVL), desaturases (SCD, FADS1, FADS2), and elongase play vital roles in lipid metabolism homeostasis [78, 79]. In tumors, lipid synthesis increases to produce more cell membrane lipids, meeting the rapidly proliferating cancer cells’ energy demands. Studies have shown that key enzymes in the fatty acid synthesis pathway, such as FASN, ACC, and ACLY, are upregulated in various cancers, including prostate cancer, breast cancer, colorectal cancer (CRC), and lung cancer. Inhibiting these enzymes can block tumor growth in vitro and vivo [80, 81]. In breast cancer, ACLY overexpression or enhanced activity is associated with tumor progression [82]. Downregulating ACLY expression affects tumor cell viability, inhibiting proliferation, invasion, and metastasis [83]. Recent studies have found that FASN expression is necessary for lipid synthesis and maintaining palmitate ester levels, particularly in the absence of exogenous lipids. Fatty acid synthesis is essential for breast tumor growth, making FASN a potential therapeutic target for breast cancer brain metastasis [84]. Additionally, studies have shown that fatty acid β-oxidation (FAO) is related to tumor chemotherapy resistance. Inhibiting FAO increases cancer cell sensitivity to drugs. Carnitine palmitoyltransferase 1B (CPT1B) is a key enzyme encoding FAO. The JAK/STAT3 signaling pathway regulates lipid metabolism, with the STAT3-CPT1B-FAO pathway promoting cancer cell stemness and chemotherapy resistance. Inhibiting JAK/STAT3 blocks breast cancer stem cell self-renewal and expression of various lipid metabolism genes like CPT1B. Blocking FAO resensitizes cancer cells to chemotherapy and inhibits cancer stem cell proliferation in mouse breast tumors [85]. Thus, interfering with lipid metabolism pathways, especially inhibiting key enzymes in lipid synthesis or oxidation or lipid transport proteins, can effectively enhance chemotherapy’s cytotoxicity on tumors, improving treatment outcomes. Amino acid metabolism Amino acids, the building blocks of proteins, are essential for synthesizing nucleotides, glutathione, and other substances. Amino acid metabolic reprogramming is related to the development of various malignancies, such as ovarian cancer, hepatocellular carcinoma, renal clear cell carcinoma, and breast cancer [86–90]. Increasing evidence suggests active amino acid metabolism in tumor cell growth signaling and immune suppression. Compared to normal breast tissue, breast cancer tissue shows significant elevations in 15 amino acids, serving as early diagnostic markers for breast cancer [91]. Glutamine, the most abundant free amino acid and the most consumed amino acid in the body participates in numerous biochemical reactions. In many tumor types, glutamine ranks second only to glucose in providing energy, indicating its close relationship with tumor occurrence and development. This section focuses on discussing and elaborating on glutamine metabolic reprogramming. Glutamine is converted to glutamate by glutaminase (GLS), maintaining normal cell functions. Studies have shown that glutamine is essential for amino acid biosynthesis pathways and can convert to TCA cycle intermediates and lactate, providing additional energy for tumor cells [92]. Glutamine metabolism provides substrates for overactivated glycolysis and OXPHOS pathways in tumor cells, inducing chemoresistance by promoting metabolic homeostasis [93]. GLS expression varies among different breast cancer subtypes [94]. Studies have found that high GLS expression is related to accelerated proliferation and malignancy in tumors like breast cancer, lung cancer, and liver cancer [95]. Inhibiting GLS activity or silencing its gene expression significantly suppresses tumor growth [92]. Previous research indicated that glutamine plays a crucial role in maintaining the activity of the mammalian target of rapamycin (mTOR) kinase [92]. Upregulated glutamine metabolism and reactivated mTOR signaling have been shown to cause resistance to HER2-targeted therapies such as lapatinib [96]. Numerous studies indicate that metabolic reprogramming of various pathways in tumor cells is related to tumor cell proliferation and chemotherapy resistance. Strategies targeting tumor cell metabolic reprogramming may enhance tumor cell cytotoxicity and are crucial for treating resistant tumors. This section discusses research and progress in targeting the regulation of metabolic reprogramming in glucose metabolism (Warburg effect and aerobic glycolysis, TCA cycle and OXPHOS, PPP), lipid metabolism, and amino acid metabolism. Targeted regulation strategies for tumor metabolic reprogramming offer new insights for more effective tumor prevention and treatment, significantly improving patient prognosis. Cell signaling regulation in metabolic reprogramming Metabolic reprogramming in tumor cells extends beyond its classical role of supporting energy production; it profoundly impacts cell signaling pathways that are crucial for cancer progression, metastasis, and resistance to therapy. One notable example is protein palmitoylation, a lipid modification that covalently attaches fatty acids to proteins [97]. Palmitoylation plays an essential role in regulating cell signaling proteins by altering their subcellular localization, stability, and interactions with other cellular components. For instance, palmitoylation can anchor signaling proteins to the plasma membrane or specific organelles, modulating their activity and enabling efficient responses to external stimuli [97]. In the context of cancer, palmitoylation of signaling proteins has been shown to promote tumor progression, enhance metastatic potential, and confer resistance to therapeutic interventions by stabilizing pro-survival signaling molecules [98]. In addition to palmitoylation, other post-translational modifications, such as phosphorylation and ubiquitination, play significant roles in regulating signaling pathways in the context of metabolic reprogramming. For example, phosphorylation of key signaling proteins by kinases such as AKT and mTOR is tightly linked to metabolic changes that promote cell growth and survival. Ubiquitination, on the other hand, regulates the degradation of signaling proteins, thereby modulating pathway activity [99]. Metabolic intermediates influence these processes by regulating the availability of substrates or cofactors required for the enzymes involved in phosphorylation and ubiquitination, further enhancing the complexity of signaling regulation in tumor cells [100]. Moreover, metabolic reprogramming can lead to increased production of specific metabolites, such as lactate, which can act as signaling molecules themselves, influencing phosphorylation and ubiquitination processes to promote cancer cell survival and therapeutic resistance [101]. Another key aspect of cell signaling regulation in metabolic reprogramming involves the upregulation of growth factor receptors, which enhances tumor cell responsiveness to mitogenic signals and the activation of their downstream signaling cascades [102]. Tumor cells frequently upregulate growth factor receptors, such as the epidermal growth factor receptor (EGFR) and the insulin-like growth factor receptor (IGFR), to amplify their response to mitogenic cues [102]. Metabolic alterations in cancer cells can increase the availability of substrates required for receptor glycosylation, which is crucial for maintaining receptor stability and function [103, 104]. Activation of these receptors subsequently triggers downstream signaling pathways, including the PI3K/AKT/mTOR and MAPK pathways, which are pivotal drivers of cell proliferation, survival, and therapy resistance [100]. Thus, metabolic reprogramming serves to support these signaling networks, enabling tumor cells to sustain growth and evade the cytotoxic effects of anticancer treatments. Furthermore, metabolic intermediates, such as glucose and amino acids, are often diverted to support these signaling pathways, thereby amplifying their pro-survival effects and enhancing resistance to treatment [102]. Metabolic reprogramming also influences the activity of signaling molecules through changes in redox balance. Reactive oxygen species (ROS) are byproducts of altered metabolic pathways, such as increased oxidative phosphorylation and glycolysis, and can act as secondary messengers in cell signaling. Elevated ROS levels activate redox-sensitive signaling pathways, including NF-κB and HIF-1α, which promote cancer cell survival, angiogenesis, and adaptation to hypoxic conditions [105, 106]. ROS can also modulate the activity of phosphatases and kinases, leading to sustained activation of proliferative and anti-apoptotic signaling pathways, thus contributing to therapeutic resistance [107]. By modulating the redox environment, tumor cells can fine-tune signaling pathways that enhance their ability to withstand therapy-induced stress and support metastatic spread. Targeting ROS production or the signaling pathways influenced by ROS could offer therapeutic opportunities for overcoming drug resistance in cancer. Recent studies have highlighted the critical role of cell signaling regulation in the metastatic spread and therapeutic resistance of breast cancer. For instance, activation of the PI3K/AKT/mTOR pathway has been linked to enhanced metastatic potential and poor prognosis in breast cancer patients [108]. Similarly, the MAPK pathway has been implicated in mediating resistance to targeted therapies, contributing to tumor recurrence and progression [109]. Additionally, alterations in metabolic enzymes that influence these pathways, such as hexokinase 2 (HK2) and pyruvate kinase M2 (PKM2), have been shown to modulate signaling cascades, further driving resistance and metastasis [110]. Understanding how metabolic reprogramming intersects with these signaling pathways provides insights into potential therapeutic strategies that could effectively target both primary and metastatic disease. Palmitoylation, along with other post-translational modifications, contributes to the dynamic adaptation of cancer cells under treatment stress by enhancing the stability, localization, and activity of key signaling proteins [97]. These modifications enable cancer cells to withstand therapeutic pressures and maintain proliferative signaling, thereby promoting survival and sustained growth under adverse conditions. By modulating key signaling proteins, these modifications facilitate cellular survival and proliferation even in the presence of anticancer drugs. Additionally, the activation of feedback loops involving kinases such as mTOR and AMPK can further sustain these modifications, creating a robust mechanism for drug resistance. Targeting palmitoylation or other regulatory enzymes—such as palmitoyl acyltransferases or kinases—may provide novel strategies to inhibit tumor growth and overcome drug resistance [111]. Understanding the intricate interplay between metabolic reprogramming and cell signaling alterations is crucial for identifying new therapeutic targets aimed at circumventing resistance mechanisms and preventing metastatic spread. Epigenetic modifications in metabolic reprogramming Metabolic reprogramming also plays a pivotal role in influencing epigenetic modifications, which are fundamental to the regulation of gene expression in tumor cells. Metabolic intermediates, such as acetyl-CoA and S-adenosylmethionine (SAM), serve as essential donors for acetylation and methylation reactions, respectively. These modifications directly impact chromatin structure and gene transcription, enabling tumor cells to adapt to environmental stressors and therapeutic pressures [112]. Acetyl-CoA, for instance, is a critical substrate for histone acetyltransferases, which catalyze the addition of acetyl groups to histone proteins. Increased levels of acetyl-CoA enhance histone acetylation, resulting in a more open chromatin structure and activation of genes that promote cell proliferation, survival, and drug resistance [113]. In this manner, metabolic changes directly influence the epigenetic landscape of tumor cells, facilitating their adaptation to adverse conditions and promoting therapeutic resistance. Additionally, acetyl-CoA can modify non-histone proteins, further affecting cellular processes such as DNA repair and transcriptional regulation, which are crucial for tumor cell survival and adaptation [114]. Similarly, SAM is a key methyl donor for DNA and histone methylation, processes that regulate chromatin condensation and gene silencing or activation. Changes in metabolic pathways can alter SAM availability, affecting the methylation status of key genes involved in cancer progression. Aberrant DNA and histone methylation patterns have been linked to the silencing of tumor suppressor genes and the activation of oncogenes, contributing to both primary and metastatic tumor growth and resistance to treatment [115]. Moreover, SAM-dependent methylation of non-histone proteins can modulate the activity of transcription factors and other regulatory proteins, thereby influencing gene expression programs that promote metastasis and drug resistance [116]. In addition to acetylation and methylation, other epigenetic modifications, such as histone phosphorylation and ubiquitination, are influenced by metabolic reprogramming. Phosphorylation of histones can alter chromatin structure and gene expression in response to stress signals, while ubiquitination of histones can either activate or repress gene transcription depending on the context [117, 118]. Metabolic intermediates, such as ATP and NAD+, are directly involved in these processes, linking metabolic state to chromatin dynamics and gene regulation. For example, ATP is required for chromatin remodeling complexes that reposition nucleosomes, thereby regulating access to DNA and influencing gene transcription [119]. NAD+, on the other hand, is involved in the activity of sirtuins, which are NAD+-dependent deacetylases that play key roles in chromatin modification and gene expression regulation [120]. Epigenetic modifications have been found to play a critical role in breast cancer metastasis and drug resistance. For instance, increased histone acetylation has been correlated with the activation of genes involved in epithelial-to-mesenchymal transition (EMT), a key process in metastasis [121]. Furthermore, DNA methylation changes have been associated with resistance to endocrine therapy in breast cancer, highlighting the importance of targeting these modifications to overcome resistance [122]. Recent studies have also shown that metabolic reprogramming can induce changes in the levels of specific epigenetic modifications, which in turn promote breast cancer metastasis and therapeutic resistance. For example, increased NAD+ availability has been linked to enhanced histone deacetylase (HDAC) activity, resulting in the repression of tumor suppressor genes and facilitating metastatic spread [123]. Additionally, alterations in ATP levels have been found to influence chromatin remodeling complexes, thereby regulating the expression of genes involved in drug resistance. The interplay between metabolic reprogramming and epigenetic modifications thus creates a feedback loop, where metabolic changes drive epigenetic alterations that further support cancer cell survival, metastasis, and resistance to therapy [124, 125]. Targeting specific epigenetic modifications, such as histone acetylation and DNA methylation, presents a promising strategy for disrupting the adaptive mechanisms of tumor cells. Inhibitors of histone acetyltransferases, methyltransferases, or other chromatin-modifying enzymes could be used to counteract the pro-survival gene expression programs activated by metabolic reprogramming. For instance, HDAC inhibitors have shown potential in reversing resistance by restoring the expression of tumor suppressor genes and sensitizing cancer cells to chemotherapy [126]. Additionally, the use of DNA methyltransferase inhibitors can help reactivate silenced tumor suppressor genes, thereby inhibiting cancer progression [127]. By combining metabolic inhibitors with epigenetic drugs, it may be possible to effectively reverse drug resistance and inhibit metastatic progression. Furthermore, targeting the metabolic enzymes that regulate the availability of key epigenetic cofactors, such as acetyl-CoA and SAM, may provide an additional layer of therapeutic intervention, ultimately disrupting the epigenetic reprogramming that supports tumor growth and survival [128]. Metabolic reprogramming of the Tumor Immune Microenvironment (TIME) on drug resistance The occurrence and development of tumors are regulated by both the genetic mutations of tumor cells and the TME [9]. The TME not only affects clinical treatment outcomes but also changes during treatment, with complex reciprocal regulatory relationships between these two factors [129, 130]. The TME refers to the complex environment in which tumor cells survive, primarily composed of the vascular system, cancer-associated fibroblasts (CAFs), immune cells, tumor-associated endothelial cells (ECs), and extracellular matrix components. The TME plays a crucial role in the occurrence, development, and metastasis of tumors, while also significantly influencing the effectiveness of tumor immunotherapy [131, 132]. As a focal point in tumor therapy, the importance of the TIME is increasingly recognized. The TIME is mainly composed of various immune cells, including T lymphocytes, B lymphocytes, tumor-associated macrophages (TAMs), natural killer cells (NKs), dendritic cells (DCs), tumor-associated neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs). The successful application of tumor immunotherapy in clinical practice has demonstrated the critical role of the immune system in combating tumors, which has now become an effective tumor treatment method alongside surgery, radiotherapy, and chemotherapy, leading to a profound transformation in tumor treatment models [133]. Studies have shown that tumor immunotherapy has also achieved significant efficacy in patients with advanced tumors [134]. However, the TME, which exerts immunosuppressive effects, remains a major barrier to improving the efficacy of tumor immunotherapy [135]. As tumors grow, immune cells in the TME undergo a series of metabolic reprogramming events, leading to changes in their phenotype (Fig. 2). Meanwhile, the reprogramming of metabolic pathways also influences the proliferation, metastasis, and immune evasion of tumor cells in the TME [136, 137]. Metabolic Reprogramming of Immune Cells in the Hypoxic Tumor Microenvironment.Under hypoxic conditions, immune cells undergo metabolic shifts that foster immunosuppression and drug resistance. TAMs rely on glycolysis and OXPHOS, generating ROS to mediate immunosuppression. B and T cells display altered glucose and glutamine metabolism, resulting in the upregulation of immunosuppressive factors such as IL-10, CD137, and CD125. TANs and MDSCs, through VISTA and associated pathways, promote immune evasion. CAFs export lactate via MCT4, activating the TGF-β1/p38 MAPK pathway, which reinforces tumor resistance Lymphocytes The effectiveness of tumor therapy mainly depends on the immune system’s ability to recognize and kill cancer cells [138]. As one of the key players in anti-tumor immunity, T lymphocytes are critical effector cells in adaptive immunity and act as the “main force” of the immune system, playing a complex and variable role in the TME (Table 2). Research has shown that immune cells utilize energy differently between quiescent and activated states, exhibiting different metabolic modes based on the state of activation. T lymphocytes are highly complex and diverse, with multiple subsets existing at different stages of development and functionality. Table 2Metabolic reprogramming in Lymphocytes in the tumor immune microenvironment. key lymphocyte types and their metabolic featuresT Lymphocytes: • Naïve T Cells: Rely primarily on OXPHOS for energy production. • Effector T Cells (Teff): Undergo metabolic reprogramming, switching from OXPHOS to aerobic glycolysis upon activation. Enhanced glucose uptake and glycolysis support rapid proliferation and effector functions. • Memory T Cells (Tm): Metabolism resembles that of naïve T cells, with low glycolytic rates and greater reliance on OXPHOS. They store energy in the form of glycogen and triglycerides. • Cytotoxic T Lymphocytes (CTLs): Express high levels of GLUT1 and glycolytic enzymes, enabling increased glucose uptake and glycolysis. Rely on fatty acid synthesis (FAS) and fatty acid oxidation (FAO) for energy and membrane biosynthesis. Glutamine metabolism is crucial for their proliferation and differentiation. • Helper T Cells (Th Cells): • Th1 Cells: Produce IFN-γ and interleukin-2 IL-2, promoting cellular immunity. • Th2 Cells: Produce IL-4, IL-5, and IL-13, supporting humoral immunity and associated with a worse prognosis in breast cancer. • Th17 Cells: Produce IL-17, playing roles in inflammation and autoimmunity. • Tregs: Preferentially use FAO and OXPHOS for energy production, with a lower rate of biosynthetic metabolism. Metabolically flexible, shifting to glycolysis during cell division.B Lymphocytes: • Activate PI3K and Akt pathways upon stimulation, promoting glucose uptake and glycolysis. • De novo fatty acid synthesis supports B cell proliferation, differentiation, and antibody production. • Amino acid metabolism is crucial for B cell survival in hypoxic environments.NKs cells: • Resting NK cells rely primarily on OXPHOS for energy. • Upon activation, glycolysis is upregulated to support effector functions such as cytokine production and cytotoxicity. • Accumulation of lactic acid and other metabolites in the tumor microenvironment can inhibit NK cell activity. Metabolic reprogramming in Lymphocytes in the tumor immune microenvironment. key lymphocyte types and their metabolic features Based on their response to antigens, T cells can be divided into naïve T cells, effector T cells (Teff), and memory T cells (Tm). T cells develop in the thymus as naïve T cells, showing zero proliferation, with metabolism in a quiescent state mainly relying on OXPHOS to produce ATP, which sustains their immune surveillance functions [139, 140]. However, once activated into Teff, their metabolism rapidly intensifies, characterized by increased intake of glucose, glutamine, arginine, and other nutrients, upregulation of glycolysis, and enhanced synthesis of proteins and lipids, thereby promoting T cell growth, proliferation, and the exertion of their effector functions [141]. It has been reported that activated CD8 + T cells can utilize both aerobic glycolysis and OXPHOS to meet their growth demands, but they primarily rely on the aerobic glycolysis pathway to enhance their effector functions [142]. The metabolic pattern of Tm resembles that of naïve T cells, with basic nutrient uptake maintained, low glycolytic rates, and greater reliance on OXPHOS for energy; simultaneously, their mitochondrial mass increases and oxygen consumption significantly rises. This metabolic mode provides an energy foundation for rapid activation upon re-encountering pathogens [143]. Moreover, Tm can utilize glucose to synthesize glycogen and convert fatty acids and glycerol into triglycerides for energy storage, enabling them to generate a rapid protective immune response when encountering pathogens again [144].Current research mainly focuses on CTLs and helper T cells, and the following sections will provide a detailed description of these two types of T cells. Cytotoxic T lymphocytes (CTLs) CTLs are the primary components of anti-tumor cellular immunity, directly killing tumor target cells by secreting perforin and granzyme or by expressing apoptosis-related factor ligands and secreting TNF-α, which bind to receptors on the target cell surface, inducing apoptosis. Studies have shown that high expression of CTL-related genes in tumors is closely associated with better prognosis [145, 146]. However, factors such as lactic acid accumulation, amino acid deficiency, and hypoxic conditions within the tumor environment can lead to CTL dysfunction [147]. After TCR recognizes tumor antigens, the PI3K-AKT-mTOR pathway is activated, leading to the upregulation of GLUT1 and amino acid transporters, as well as enhanced glycolysis and glutamine metabolism [148, 149]. When T cells are activated and differentiate into cytotoxic Teff, their metabolic pathways shift from OXPHOS to aerobic glycolysis, with GLUT1 expression upregulated and glucose uptake increased, further enhancing their tumor-killing capabilities. Additionally, the FAS metabolic pathway is strengthened, with mTOR regulating the upregulation of key enzymes in the FAS pathway, such as sterol regulatory element-binding proteins (SREBPs), fatty acid synthase, and acetyl-CoA carboxylase, promoting the proliferation of cytotoxic Teff cells [150]. Glutamine (Gln) is crucial for CTL proliferation and differentiation, and Gln depletion reduces CTL proliferation and cytokine production. Upon T cell activation, Gln transporter expression is upregulated, increasing Gln uptake [151]. In the TME, glucose deficiency inhibits the activation of relevant signals, leading to impaired CD8 + T cell differentiation, thereby causing anti-tumor functional impairment [152]. Helper T cells (th cells) Helper T cells are effector cell subsets derived from CD4 + T cells and can be further classified into Th1, Th2, Th17, and regulatory T cells (Tregs). Different Th cell subsets regulate the functions of CTLs and macrophages by secreting various cytokines. Th1 cells promote cellular immunity by producing interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2), while Th2 cells assist B cells in promoting humoral immunity through the secretion of IL-4, IL-13, and other cytokines. In breast cancer, the upregulation of Th1-related pathways is associated with a better prognosis, whereas the upregulation of Th2-related pathways correlates with a worse prognosis [153, 154]. Moreover, in the breast cancer tumor stroma, the number of infiltrating Th2 cells is significantly higher than that of Th1 cells [155, 156]. Th2 cells not only promote the growth of primary tumors [155, 156]but also activate M2-type TAMs by secreting cytokines such as IL-4, further promoting breast cancer invasion and metastasis [157, 158]. The concept of Tregs was first proposed by Sakaguchi and colleagues in 2002. Tregs are a subset of CD4 + T cells characterized by the expression of CD4 and CD25. This subset has significant immunoregulatory functions and can suppress T cell-mediated anti-tumor immunity, playing a crucial role in tumor immune evasion. Tregs are widely infiltrated in the TME [159], where they can suppress the anti-tumor functions of NK cells, CTLs, and Th1 cells [160–164]. In animal models, Tregs are closely associated with the process of breast cancer lung metastasis [155, 159], and their high infiltration in the TME typically indicates a poor prognosis [165, 166]. In terms of metabolism, Tregs primarily rely on the TCA cycle coupled with OXPHOS, FAO, and glycolysis to support their survival and differentiation, which helps maintain their immunosuppressive functions. Tregs exhibit a lower rate of biosynthetic metabolism, mainly fueled by FAO [167], however, during cell division, Tregs shift to a glycolysis-dominant metabolic pathway to meet the biosynthetic demands of growth and proliferation [168]. In the TME, the glycolytic pathway of CD4 + T cells is downregulated, shifting towards FAO and OXPHOS to obtain energy and synthesize materials, thereby promoting the expression of FOXP3 in CD4 + T cells, facilitating Treg differentiation [169]. Tregs further regulate metabolism through FOXP3, downregulating glycolysis and promoting OXPHOS, allowing them to survive and exert immunosuppressive effects in the low-glucose TME. The lipid metabolism pathway is also crucial for the immunosuppressive function of Tregs. Studies have found that lipid metabolism-related genes are more abundantly expressed in tumor-infiltrating Tregs [170]. Additionally, in vitro proliferation studies have shown that blocking FAS (fatty acid synthesis) has a more significant impact on Tregs than blocking FAO, suggesting that FAS plays an important role in regulating the active proliferation of cancer-associated Tregs. Furthermore, research has shown that large amounts of glutamate produced by glutamine metabolism in tumor cells can promote the expression of the metabolic glutamate receptor 1 in Tregs, increasing their uptake and utilization of glutamate, thereby promoting Treg proliferation and infiltration [171]. In metastatic melanoma, Tregs can upregulate ARG2 expression, enhancing their ability to uptake arginine, which promotes their proliferation and recruitment to tumor tissues while inhibiting anti-tumor immune responses [172]. B lymphocytes B lymphocytes play a central role in humoral immunity against tumors, primarily through the production and secretion of antibodies, which are key immune-active substances (Table 2). Activated B cells can differentiate into plasma cells, infiltrating the tumor and producing large amounts of cytokines and antibodies [173]. These antibodies mediate anti-tumor immune responses through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and complement activation [173]. Additionally, B cells can promote the formation of tumor-associated tertiary lymphoid structures (TLS). TLS are ectopic lymphoid structures mainly composed of B cells, T cells, DCs, and macrophages [174]. In the TME, TLS can enhance the infiltration of immune cells into tumor tissues and are significantly associated with favorable patient prognosis. For example, in patients receiving immunotherapy, high expression of TLS in tumor tissues is associated with a positive response to treatment, suggesting that TLS may serve as an important biomarker for predicting the efficacy of tumor immunotherapy [175–178]. In recent years, although the role of T cells in tumor immunity has been widely studied, research on the energy metabolism of B cells remains relatively limited. In terms of glycolysis, B cells, upon activation by lipopolysaccharides (LPS) or surface antigens, activate intracellular phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt), promoting glucose uptake and shifting the metabolic mode to glycolysis-dominant [179]. Conversely, if the glycolytic pathway is inhibited, B cell proliferation and antibody production capacity will be significantly suppressed [180]. Regarding lipid metabolism, de novo fatty acid synthesis induced by endogenous ATP citrate lyase promotes B cell proliferation, differentiation, and antibody secretion [181]. Additionally, amino acid metabolism is crucial for B cell survival in hypoxic environments [182]. In summary, B cells play an indispensable role in tumor development and the body’s anti-tumor immune regulation. However, the molecular mechanisms of B cell metabolic reprogramming within the TME remain incompletely understood and require further exploration in the future. Tumor-Associated macrophages (TAMs) Cancer-related inflammation is one of the ten biological hallmarks of tumors [183], and inflammation, as a critical component of the TME, plays a key role. TAMs are the major constituents of immune cell infiltration within tumors and play an extremely important role in mediating tumor inflammation and progression (Table 3). Macrophages that infiltrate the local tumor site are generally referred to as TAMs. As crucial components of the TME, TAMs are key members of the innate immune cells and serve as a bridge connecting the body’s innate and adaptive immunity. They mainly function by phagocytosing and digesting cellular debris and pathogens, activating other immune cells to combat pathogen invasion, and thereby playing a critical role in tumor therapy. In some solid tumors, macrophages account for more than 50% of the cells within the TME [184].TAMs can be classified into pro-inflammatory M1 macrophages and anti-inflammatory M2 macrophages based on their functions. M1-type TAMs exert anti-tumor effects, while M2-type TAMs promote tumor invasion and metastasis [157, 158]. Due to the dynamic changes in the TME during different stages of tumor development, these two types of macrophages coexist in varying proportions. The dynamic switching between M1 and M2 phenotypes, known as polarization, plays a crucial role in tumor immune evasion [185]. Research indicates that in the early stages of tumor development, TAMs primarily exhibit a pro-inflammatory, anti-tumor M1 phenotype, while as the tumor proliferates and metastasizes, TAMs gradually shift to an anti-inflammatory, pro-tumor M2 phenotype [186]. M2 macrophages downregulate immune-stimulatory factors such as IL-12 and highly express immune-suppressive factors like IL-10, suppressing their tumoricidal activity and inhibiting the cytotoxicity of CD8 + T cells within the tumor. In the stromal tissue of human breast cancer, TAM infiltration is inversely correlated with the number of CD8 + T cells [158], and increased M2 TAM infiltration is typically associated with poor prognosis [187, 188]. Table 3Metabolic reprogramming in Non-Lymphocyte immune cells in the tumor immune microenvironmentKey Non-Lymphocyte Types and Their Metabolic Features: Tumor-Associated Macrophages (TAMs): • M1 Macrophages: Demonstrate a metabolic shift towards aerobic glycolysis, like the Warburg effect, with high glycolytic activity and production of ROS. This metabolic state supports their pro-inflammatory and anti-tumor functions. • M2 Macrophages: Rely more on OXPHOS for energy production, with increased fatty acid uptake and oxidation. This metabolic profile is associated with their anti-inflammatory and pro-tumorigenic roles. Tumor-Associated Neutrophils (TANs): Have limited mitochondria and therefore depend less on OXPHOS. Rely primarily on aerobic glycolysis and the pentose phosphate pathway (PPP) for energy production. Upregulate GLUT1 expression, and NADPH produced by the PPP supports their functions, including the release of pro-tumorigenic factors. Dendritic Cells (DCs): Immature, resting myeloid-derived DCs rely on OXPHOS for energy. Upon activation, they switch to glycolysis to support antigen presentation and immune effector functions, enhancing their ability to stimulate T cell responses. Myeloid-Derived Suppressor Cells (MDSCs): Utilize a combination of glycolysis, the tricarboxylic acid (TCA) cycle, and OXPHOS to support their immunosuppressive functions. Undergo metabolic reprogramming, including increased fatty acid uptake and oxidation, which enhances their survival and immunosuppressive capabilities, contributing to tumor progression and resistance to immunotherapy. Metabolic reprogramming in Non-Lymphocyte immune cells in the tumor immune microenvironment Under normal physiological conditions, macrophages primarily obtain energy through the OXPHOS metabolic pathway [189]. However, upon stimulation by substances such as LPS, peptidoglycans, and cytokines (e.g., TNF-α, IL-1, IL-4, IL-10), macrophages undergo polarization and metabolic reprogramming. M1 and M2 TAMs exhibit different metabolic modes, which will be discussed separately below. M1 Polarized macrophages In the early stages of tumorigenesis, pro-inflammatory factors in the TME, such as IFN-γ and TNF-α, induce macrophages to polarize towards the M1 phenotype. The primary role of M1 TAMs is to kill tumor cells by secreting large amounts of inflammatory factors, including ROS, interleukins (ILs), TNF-α, and nitric oxide (NO) [190]. Among these, ROS is crucial for the phagocytic activity of macrophages and for presenting antigens to T cells. To enhance their pro-inflammatory functions and compete with tumor cells for nutrients, M1 TAMs exhibit a “Warburg-like metabolism” like that of tumors [191]. Upon activation, the metabolic pathway of M1 TAMs shifts from OXPHOS of glucose to predominantly glycolysis, generating ROS through the PPP to exert anti-tumor effects [192, 193]. This metabolic shift is also accompanied by increased lactate production, reduced oxygen consumption, and upregulation of glutamine breakdown. This shift in glucose metabolism allows M1 macrophages to rapidly provide a large amount of metabolic intermediates and energy [194]. During metabolic reprogramming, the TCA cycle in M1 macrophages is disrupted, leading to the accumulation of succinate and citrate. Succinate stabilizes HIF-1α by inhibiting prolyl hydroxylase activity, thereby accelerating glycolytic metabolism and driving the inflammatory response [195]. Citrate, as a precursor for the synthesis of NO and prostaglandins, also participates in the inflammatory response [196]. Additionally, the hypoxic environment in the TME activates HIF-1α in M1 TAMs, inducing the overexpression of glycolysis-related genes such as GLUT1 and HK2. Upregulated glycolysis also synthesizes more NADPH through the PPP to protect cells from ROS damage. NADPH is not only used to maintain cellular redox balance and biosynthetic metabolism but also further promotes the production of ROS and NO [197]. In vitro studies have shown that inhibiting the glycolytic pathway of M1 macrophages can revert them to an undifferentiated state, while removing the inhibitor restores the M1 phenotype, indicating that the glycolytic pathway is central to the regulation of macrophage polarization [198]. Moreover, in terms of fatty acid metabolism, M1 TAMs promote de novo fatty acid synthesis by downregulating FAO pathways to meet the biosynthetic demands of cellular inflammatory factors [199]. In amino acid metabolism, the arginine metabolism pathway in M1 TAMs is particularly notable. M1 TAMs primarily metabolize arginine via NO synthase to produce NO and citrulline, where NO is a critical effector molecule in tumor cell killing [200]. However, in many tumors, excessive NO not only promotes tumor angiogenesis, proliferation, and metastasis but is also associated with resistance to DNA-damaging drugs and anti-tumor immunity [201, 202]. M2 polarized macrophages During the stages of tumor proliferation and metastasis, several ILs in the TME, such as IL-4, IL-10, and IL-13, induce macrophages to polarize towards the M2 phenotype [203]. Under the influence of the TME, M2 macrophages express major histocompatibility complex (MHC), IL-10, IL-12, and other anti-inflammatory cytokines, promoting immune suppression, angiogenesis, tumor cell extravasation, and metastasis [190]. Although M2 macrophages also require glycolysis to provide substrates and energy for cytokine synthesis, their glycolytic levels are significantly lower compared to M1 macrophages, and they maintain an intact TCA cycle with markedly increased oxygen consumption upon activation. In this context, M2 macrophages primarily rely on the OXPHOS metabolic pathway for energy production [204]. In terms of lipid metabolism, M2 macrophages uptake lipids through CD36, followed by lipolysis via lysosomal acid lipase. FAO is also a critical energy source for M2 macrophages. This process sacrifices low levels of glycolysis, highly expresses CD36, and upregulates FAO levels to promote mitochondrial OXPHOS [205]. Studies have shown that lipid metabolism reprogramming is crucial for TAM polarization and function [131]. M1 and M2 macrophages are characterized by fatty acid synthesis (FAS) and FAO, respectively [206]. Modifying lipid metabolism to promote FAO can drive the polarization of M2 macrophages. For instance, in hepatocellular carcinoma, the necroptotic core factor RIPK3 is significantly downregulated in macrophages, leading to reduced ROS and the activation of peroxisome proliferator-activated receptors (PPARs), which promotes FAO and induces M2 polarization [207], thereby generating a pro-tumor immune response. Tumor-Associated neutrophils (TANs) Neutrophils serve as the body’s first line of defense against bacteria, viruses, and other pathogens and play a crucial role in the activation and regulation of innate and adaptive immunity [208, 209]. TANs are primarily derived from peripheral blood neutrophils and represent significant inflammatory infiltrating cells within the TME, closely associated with tumor occurrence and development [210]. Studies have shown that TANs can produce neutrophil extracellular traps (NETs), indicating that neutrophils may play an important role in the TME [211]. NETs are web-like structures composed of neutrophil DNA modified by granule proteins, which have been demonstrated to participate in the process of cancer metastasis [212]. Research indicates that neutrophils, by releasing NETs, deliver intracellular substances into the microenvironment, thereby exacerbating local inflammation and promoting tumor metastasis [213]. In addition to NETs, TANs can acquire either an anti-tumor (N1) or pro-tumor (N2) phenotype upon recruitment to the TME [214]. Increasing evidence suggests that TANs are not “neutral” but can differentiate into different phenotypes depending on the environmental context, similar to the M1/M2 polarization of macrophages [215]. N1 TANs mediate anti-tumor activity directly through ADCC and indirectly by producing hydrogen peroxide, pro-inflammatory cytokines, and activating T cells. In contrast, N2 TANs promote tumor development by highly expressing ARG1 and inducing the production of NO synthase, which suppresses the activity of anti-tumor CD8 + T cells [216, 217]. Additionally, the relationship between the numbers of TANs, Tregs, and TAMs can serve as a predictive model for evaluating the prognosis of tumor patients [218]. Metabolically, TANs have few mitochondria in their cytoplasm and thus rely little on OXPHOS for energy production, instead depending mainly on aerobic glycolysis and the PPP for energy [219, 220]. In TANs, GLUT1 expression is upregulated, but when the GLUT1 gene is knocked out, TANs show significantly reduced glucose uptake and lower survival rates [221]. The NADPH generated by the PPP is a cofactor for NADPH oxidase, which helps TANs exert their anti-tumor immune functions. Research indicates that tumor cells can induce an oxidative phenotype in TANs through stem cell factor (SCF)/cKit signaling, enhancing their mitochondrial OXPHOS function [222]. Even in glucose-deficient conditions, TANs can maintain NADPH production and ROS levels through FAO, thereby exerting immunosuppressive functions [222]. Natural killer cells (NKs) NK cells are important innate immune cells in the TME and belong to a subset of innate lymphocytes capable of generating cytotoxicity and secreting cytokines without requiring antigen sensitization. NK cells do not rely on MHC-I molecules, allowing them to directly kill tumor cells and mediate antiviral and anti-tumor responses in the body, making them the first line of defense against cancer [223]. Additionally, NK cells could regulate other immune cells and promote tissue growth [224]. However, within the TME, NK cell infiltration decreases, their phenotype changes, their activity declines, and their tumor-killing functions are inhibited. The activation and cytotoxic capabilities of NK cells are primarily regulated by the balance between activating and inhibitory receptors on their surface. When inhibitory receptors on NK cells bind to their corresponding ligands on tumor cells, NK cell cytotoxicity is suppressed; conversely, when activating receptors on NK cells bind to ligands on tumor cells, NK cell cytotoxicity is activated [225]. Compared to normal breast tissue, the number of NK cells within breast cancer tumors is significantly reduced [226–228]. Activated NK cells can directly release cytotoxic granules to lyse tumor cells and secrete IFN-γ and TNF-α to activate adaptive immune responses [229]. Moreover, NK cells can regulate immune responses by producing cytokines and chemokines and interacting with other immune cells, playing an important role in inhibiting tumor occurrence and development [230]. NK cells exhibit different metabolic patterns in different states: in the resting state, NK cells primarily obtain energy through OXPHOS [231], while upon activation, the glycolytic pathway is upregulated [232]. After NK cell activation, the expression of SREBPs and the mammalian target of rapamycin complex 1 (mTORC1) is upregulated, enhancing both aerobic glycolysis and OXPHOS metabolic pathways [233]. However, the excessive accumulation of metabolites in the TME can inhibit NK cell activity. For instance, the accumulation of lactic acid in the TME can lower the pH within NK cells, leading to mitochondrial stress and metabolic dysfunction, with ROS gradually accumulating, ultimately inducing NK cell apoptosis [234]. Excessive lipid metabolism can also impair the normal function of NK cells. The upregulation of lipid transporters leads to excessive uptake of fatty acids by cells, activating the PPAR-γ/PPAR-δ signaling pathway, inhibiting NK cell metabolic activity, and inducing cytotoxicity [235]. Furthermore, nutrient deficiency in the TME can inhibit NK cell activity. NK cells require significant glucose uptake for glycolysis to provide energy and substrates for synthesizing inflammatory cytokines and other metabolic pathways. Glucose deficiency in the TME can severely inhibit the glycolytic pathway in NK cells [236]. Additionally, amino acid deficiency can also inhibit NK cell activity. The levels of arginine, leucine, and glutamine affect the mTOR signaling pathway in NK cells [237]. In summary, the TME alters the metabolic pathways of NK cells through various mechanisms, leading to a significant decline in NK cell cytotoxicity. Dendritic cells (DCs) As initiators of the immune system, DCs are the most important antigen-presenting cells in tumor immunity, participating in antigen presentation and the activation of T lymphocyte immune responses. DCs can effectively capture and present tumor antigens and secrete cytokines and growth factors that enhance the activity of T cells, NK cells, and other immune cells, thus establishing a comprehensive anti-tumor immune response and playing a critical role in immunotherapy. However, recent studies have shown that DCs within the TME exhibit immunosuppressive effects, weakening their functions in anti-tumor immunity. DCs can be categorized into myeloid DCs and plasmacytoid DCs based on their origin and into mature DCs and immature DCs based on their function. In a resting state, myeloid-derived immature DCs primarily rely on mitochondrial OXPHOS to oxidize glucose. Upon activation by Toll-like receptor (TLR) agonists, the intracellular glycogen stored in these cells is metabolized primarily through glycolysis [238], rapidly providing energy, and their metabolic pathway shifts from OXPHOS to aerobic glycolysis to support their metabolic demands and antigen-presenting functions [239]. During this process, HIF-1α, PI3K, and Akt signaling are involved in the metabolic reprogramming of DCs [240]. Unlike T cell metabolic reprogramming, which primarily serves cell proliferation and growth, changes in the metabolic mode of DCs mainly support the synthesis, expression, and secretion of immune mediators [241]. Within the TME, DCs may weaken their antigen-presenting ability through immunosuppressive mechanisms, thereby affecting the anti-tumor immune response. Research indicates that in some tumors, DCs exhibit a resistant phenotype, secreting inhibitory cytokines such as IL-10 to suppress T-cell activity, thereby aiding tumor immune evasion. Furthermore, tumor cells can directly influence the differentiation and function of DCs, further weakening their antigen-presenting function. These mechanisms enable tumors to evade immune surveillance, thereby promoting tumor progression. Myeloid-derived suppressor cells (MDSCs) MDSCs are a highly heterogeneous group of immune suppressive cells derived from the bone marrow and are widely expressed in various primary and metastatic tumors [242]. The survival and immunosuppressive functions of MDSCs depend on the production of ATP through three combined metabolic pathways: glycolysis, the TCA cycle, and OXPHOS. In terms of glucose metabolism, MDSCs adapt to the hypoxic and nutrient-deficient TME by regulating glycolysis and OXPHOS metabolic pathways to maintain their immunosuppressive effects [243]. Studies have shown that the glycolytic intermediate PEP in the TME can prevent excessive ROS production, protecting MDSCs from ROS-mediated apoptosis [16]. Additionally, the enhancement of tumor cell glycolysis can promote the expression of granulocyte colony-stimulating factors, further recruiting MDSCs into the microenvironment and inhibiting anti-tumor immune responses [244]. On the other hand, the increased aerobic glycolysis of tumor cells generates large amounts of lactic acid, leading to its accumulation in the TME, and imposing metabolic stress on infiltrating immune cells. Lipid metabolism also plays a critical role in MDSCs. Studies have found that MDSCs can utilize FAO as their primary energy source, characterized by increased fatty acid uptake, mitochondrial mass, upregulation of key enzymes in the OXPHOS pathway, and increased oxygen consumption. Lipid metabolism not only supports MDSC survival but also regulates their immunosuppressive functions. The upregulation of lactic acid in the TME enhances the ability of MDSCs to uptake lipids, making FAO the primary energy source instead of glycolysis. The loss of CD36 or inhibition of FAO disrupts the immunosuppressive functions of MDSCs, thereby improving the effectiveness of immunotherapy and slowing tumor progression [245].In amino acid metabolism, MDSCs highly express ARG1, which metabolizes arginine into ornithine and urea, a process that inhibits T-cell function [136].In conclusion, MDSCs maintain their immunosuppressive functions through various metabolic pathways and promote tumor resistance and progression by regulating metabolic pathways in the TME. Understanding and intervening in these metabolic pathways may provide new strategies for tumor treatment. Mechanisms of immune cells in tumor drug resistance We have previously discussed the characteristics and changes in the metabolic pathways of various immune cells within the TME during tumor development. The following section will focus primarily on the role of immune cells in the TME in regulating tumor cell drug resistance. Tumor resistance is currently one of the main obstacles to cancer treatment, leading to treatment failure and disease progression, and its mechanisms vary depending on tumor type and treatment strategy. Immune cells in the TME directly or indirectly mediate the resistance of tumor tissues to radiotherapy, chemotherapy, and immunotherapy. The imbalance between pro-tumor and anti-tumor immunity alters the disease model and affects local lesions, leading to the development of resistance [246]. Within the TIME, Tregs suppress anti-tumor immune responses, making them a key factor in tumor immune evasion and closely linked to tumor resistance. Studies have found that Tregs rely on CCR4 expression to migrate into tumors with high expression of CCL17 and CCL22, a mechanism that plays a critical role in tumor immune resistance [247]. Additionally, Tregs expressing CCR4 exhibit stronger immunosuppressive functions, secreting more cytokines such as IL-10 and IL-35, which inhibit the function of cytotoxic T cells, thereby promoting tumor immune evasion [248]. Furthermore, Tregs use their surface CTLA-4 molecules to increase the expression of indoleamine 2,3-dioxygenase (IDO) in antigen-presenting cells, raising the concentration of IDO in the TIME, which in turn recruits and activates more Tregs, promoting tumor progression and leading to resistance [249]. Studies have highlighted the crucial role of TAMs in promoting tumor development and resistance. First, TAMs induce resistance by counteracting drug-induced apoptosis in tumor cells. For example, gemcitabine, commonly used in the treatment of pancreatic cancer, often fails to achieve the desired therapeutic effect due to tumor resistance. However, pancreatic cancer cells co-cultured with TAMs can reduce the apoptosis of tumor cells induced by gemcitabine through the Caspase-3 apoptotic pathway. Second, TAMs can also secrete cytokines that induce changes in the gene regulatory pathways of tumor cells, leading to resistance. For instance, TAMs can mediate chemotherapy resistance and radiotherapy resistance by upregulating the signal transducer and activator of transcription 3 (STAT3) signaling pathway [250]. Additionally, TAMs can induce tamoxifen resistance by secreting the chemokine CCL2, which activates the PI3K/Akt/mTOR signaling pathway [251]. In early breast cancer patients, TAMs can inhibit the function of Teff by inducing Arg1-mediated L-arginine hydrolysis, thereby affecting anti-tumor immune responses [252]. In terms of immunotherapy, TAMs in various solid tumors can influence the expression of PD-1 and PD-L1 through multiple pathways, thereby affecting the efficacy of PD-1 and PD-L1 inhibitors [253]. Currently, research on the role of TANs in tumor resistance is relatively limited, but studies have shown that TANs infiltrating tumor sites primarily mediate tumor resistance through NETs [254]. NETs are widely present in various cancers, and related studies have shown that NETs-associated matrix metalloproteinase 9 (MMP9) is responsible for activating TGF-β secreted by tumor cells, leading to chemotherapy resistance [255]. Furthermore, NETs can affect the proliferation and activation of T cells and NK cells, thereby limiting the effectiveness of immunotherapy. NKs play a vital role in anti-tumor immune responses. However, tumor cells can evade NK cell cytotoxicity by altering the expression of surface receptors and releasing immunosuppressive factors, thus promoting tumor development and resistance. Research shows that tumor-associated NK cells are enriched in tumors, but their anti-tumor function is weakened, and they are closely associated with resistance to immunotherapy and poor prognosis [256]. DCs, as antigen-presenting cells, also play a certain role in tumor resistance. Studies have shown that DCs may promote tumor progression by inducing tumor resistance. For example, in the bone marrow of multiple myeloma (MM) patients, the infiltration of DCs increases, and co-culturing MM cells with DCs can enhance MM cells’ resistance to drug-induced apoptosis by bortezomib and lenalidomide [257]. Additionally, studies have shown that DCs can induce tumor resistance by secreting cytokines such as IL-6, which activate the NF-κB signaling pathway in tumor cells [258]. MDSCs have strong immunosuppressive functions, promoting tumor development, metastasis, and resistance by inhibiting the activity of T cells, NK cells, and DCs [259]. MDSCs participate in the formation of tumor resistance through various mechanisms. First, MDSCs can induce tumor cell resistance by secreting cytokines that influence gene expression and signaling pathways in tumor cells. Second, MDSCs can inhibit the proliferation and function of tumor-specific immune cells [260, 261]. Additionally, MDSCs can induce tumor cells to express immune checkpoint molecules such as PD-L1 and CTLA-4, reducing the tumor’s sensitivity to immunotherapy [262, 263]. Furthermore, MDSCs can modulate MHC I expression, preventing cytotoxic T cell antigen presentation, leading to tumor immune tolerance [264]. In summary, metabolic alterations in tumor cells not only affect the antigen presentation and recognition abilities of immune cells but also influence the function of tumor cells through the metabolic reprogramming of immune cells, ultimately resulting in changes in local immune functions. Leveraging the potential of immune cells within the TME to regulate tumor resistance offers significant opportunities. Clarifying the specific mechanisms by which immune cells mediate tumor resistance in the TME and developing targeted strategies against these cells can significantly enhance the effectiveness of tumor treatment. With advancements in technology and a deeper understanding of the tumor immune microenvironment, more targeted therapeutic strategies are expected to emerge in the future, providing patients with more effective personalized treatment options, and ultimately improving the survival rates and quality of life for cancer patients. Vascular niche metabolic reprogramming on drug resistance The vascular system not only provides a transport pathway for nutrients, oxygen, and metabolic products to tumor tissues but also plays a crucial role in tumor metastasis [265]. Due to the rapid proliferation and high metabolic rate of tumor cells, tumors initiate pathological angiogenesis by disrupting the balance between pro-angiogenic and anti-angiogenic factors, leading to the excessive formation of capillary networks within the TME and creating a heterogeneous tumor vascular system. The initiation of angiogenesis is typically triggered by the overproduction of angiogenic factors such as vascular endothelial growth factor (VEGF), placental growth factor (PIGF), and angiopoietin-1. Upon stimulation, various components of blood vessels begin to respond: endothelial progenitor cells migrate from the bone marrow, pericytes detach, blood vessels dilate, and the basement membrane and extracellular matrix degrade; ECs migrate to the perivascular space, proliferate continuously, change shape, and adhere to each other, forming new lumens [266]. The newly formed capillaries intertwine, creating a capillary network within the TME that specifically provides nutrients and oxygen to the tumor, thereby driving tumor growth and progression. The chaotic structure of blood vessels in the TME, often accompanied by leakage and hemorrhage, is closely related to the excessive secretion of VEGF [267]. Through the classical VEGFR1/R2 signaling pathway, VEGF mediates the proliferation of originally quiescent ECs [268, 269]. The hypoxic environment within the tumor prevents hypoxia-inducible factors (HIF) from being hydroxylated by prolyl-4-hydroxylase, thereby maintaining their stability and inducing VEGF production. Moreover, the expression of VEGF is also regulated by other hypoxia-regulated genes, such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and oncogenic mutations (e.g., VHL, RAS, WNT-KRAS signaling pathway genes). VEGF derived from tumor cells and surrounding stroma binds to different subtypes of VEGF receptors (VEGFRs), neuropilin receptors, and heparan sulfate proteoglycans (HSPGs) on ECs, inducing ECs survival, proliferation, and migration, promoting angiogenesis, and altering vascular permeability. Among these, the VEGF-VEGFR2 pathway is the classical pathway regulating ECs growth. VEGF activates the ERK pathway through VEGFR2, altering the cell cycle and arachidonic acid metabolism, thereby promoting ECs proliferation and prostaglandin I production. Additionally, pro-angiogenic factors such as VEGF, FGF2, PIGF, TNF, and BV8 can increase vascular permeability [270], leading to plasma protein extravasation, forming a temporary matrix that allows activated ECs migration and creating the necessary conditions for angiogenesis initiation in the previously quiescent vascular system. Certain angiogenic signal receptors, such as VEGFR-2 and Notch receptors, undergo extensive glycosylation modifications during protein processing, which regulate their affinity for corresponding ligands. Tumor ECs exhibit increased glucose uptake, enhanced glycolytic activity, and altered glycolytic intermediates toward the PPP, fatty acid biosynthesis, and serine biosynthesis pathways. Uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) and guanosine diphosphate-mannose (GDP-Man), as major precursors for glycosylation, are regulated by the hexosamine biosynthesis pathway (HBP). When glucose uptake in ECs within the TME increases, HBP, as a branch pathway of glucose metabolism, is correspondingly enhanced, providing metabolic substrates for upregulated glycosylation modifications and promoting cell glycosylation [271]. Although the mechanism by which glycan chains regulate angiogenic activity is not fully elucidated, the dual role of glycosylation in activating angiogenic signal receptors has been preliminarily discovered. Studies have shown [272] that sialylation modification at Asn-247 of VEGFR2 facilitates ligand-mediated signal activation, while α2-6-linked sialic acid residues on N-glycans impede receptor activation and signal transduction. Notch receptors, as contributors to breast cancer, are influenced by glycosylation, regulating their responsiveness to DLL4 and Jagged1 ligands, mediating ECs sprouting and proliferation [270]. The activity of ligands is similarly regulated by metabolism-mediated glycosylation modifications. Research by Ersilia Varone et al. revealed that the loss of ENO1 in breast cancer selectively impairs VEGFA-mediated angiogenesis. In their subsequent follow-up study, they found that the loss of ENO1 disrupts the oxidative balance in the endoplasmic reticulum [273], leading to an increase in the glycosylation levels of VEGF, thereby regulating angiogenesis [274]. Furthermore, the hypoxic TME upregulates the expression of fructose transporters and multiple fructose metabolism enzymes in ECs, with fructose metabolism-enhancing ECs migration and proliferation by activating AMPK signaling and upregulating mitochondrial respiration, ultimately promoting tumor angiogenesis and metastasis [275]. The abnormal proliferation behavior of ECs caused by metabolic alterations provides new insights into explaining the resistance of certain anti-angiogenic cancer therapies [276, 277]. For example, Gal1 triggers VEGF-like signaling by binding to specific N-glycan sites, including phosphorylation of VEGFR2, ERK1/2, and Akt in ECs, leading to tumor resistance to anti-VEGF therapy [278]. Inhibiting the glycolytic pathway PFKFB3 in ECs can induce tumor vascular normalization, inhibit tumor cell metastasis, and improve chemotherapy efficacy [279]. Therefore, targeting the metabolic pathways of ECs to regulate glycosylation levels may provide new directions for overcoming tumor resistance to anti-angiogenic therapies. ECs also co-regulate the expression of OPN through Twist1 and SATB1, promoting the transformation of monocytes into immunosuppressive macrophages, which may be one of the reasons for tumor resistance to CAR T cell immunotherapy [280]. Studies have also shown that ECs can effectively induce epithelial-mesenchymal transition (EMT) in basal-like breast cancer cells [281]. In breast cancer, PTN secreted by ECs interacts with NRP1 [282], stimulating tip cell sprouting, leading to the accumulation of immature perivascular cells in the affected skin of patients, ultimately enhancing cancer invasiveness and metastatic potential. ECs induce EMT in squamous cell carcinoma by secreting epidermal growth factor (EGF). Secreted fibronectin extra domain A induces EMT in CRCcells by interacting with integrin α9β1 on CRC cells [283], thereby promoting CRC metastasis. This interaction activates FAK and Rac signaling, producing polarized cytoskeletons and enhancing CRC cell invasiveness. Like epithelial cells, ECs can transform into mesenchymal-like cells through endothelial-mesenchymal transition (EndMT) [284]. During EndMT, ECs lose endothelial junctions, acquire mesenchymal markers, and develop invasive and migratory capabilities [285, 286]. EndMT not only disrupts vascular integrity but also promotes cancer cell migration across the endothelial layer. The TGFβ and Notch signaling pathways play crucial roles in EndMT [286], which is considered one of the known sources of CAFs [287]. These CAFs not only provide essential signals for cancer cell dedifferentiation, proliferation, and survival but also promote metastasis by regulating the tumor immune microenvironment [288]. Therefore, ECs indirectly promote cancer cell invasiveness and migratory properties through EndMT. The above discussion indicates that the vascular microenvironment within tumors is closely related to tumor immunity [289], and targeting the signaling pathways within ECs may bring innovative breakthroughs to the field of cancer immunotherapy. Stromal cells metabolic reprogramming on drug resistance The stromal cells in the TME primarily include CAFs, ECs, and tumor-associated stromal cells [290]. The categories and enrichment levels of stromal cells vary widely across different cancer types, subtypes, and developmental stages [291]. In breast cancer, the hypoxic, low pH, metabolically reprogrammed TME fosters pre-metastatic organ tropism by altering various cytokines, metabolic molecules, and signaling pathways [290]. The tumor stroma forms the structural backbone of the TME, mediating interactions between tumor cells and immune cells and remodeling the TME to support tumor development, enhance tumor cell invasiveness and drug resistance, and reduce immune surveillance, thereby exacerbating immune escape [292]. CAFs play a crucial role in influencing the extracellular matrix and stiffness of tumor cells, interacting with tumor and immune cells through paracrine and other pathways, thus affecting their occurrence and development Additionally, CAFs enhance the activity and proliferation of immunosuppressive myeloid cells by releasing metabolic products, inflammatory factors, and chemotactic agents, which promote lymphocyte differentiation and reduce the activity of anti-tumor immune cells, thus forming an immunosuppressive microenvironment that leads to immune escape and reduced immunotherapy efficacy [293]. CAFs can exacerbate immune suppression and tumor cell drug resistance through metabolic reprogramming [294]. The hypoxic characteristics of the TME may induce epigenetic changes in CAFs’ glycolysis, enhancing their glycolytic activity. In terms of energy utilization, CAFs induce and strengthen tumor cell lactate utilization through energy crosstalk with tumor cells, significantly increasing lactate levels in the TME, thus enhancing energy supply and the activity of tumor and immunosuppressive cells. For example, CAFs form a metabolic symbiosis with tumor cells [295]. In cancers with high glycolytic activity, such as prostate cancer, CAFs produce large amounts of lactate through anaerobic glycolysis, which is then utilized by prostate cancer cells. This intercellular communication causes CAFs to upregulate GLUT1 and MCT4 through the “reverse Warburg effect,” promoting glucose utilization and glycolytic activity [296], while prostate tumor cells downregulate GLUT1 and upregulate MCT4 to enhance aerobic oxidation and lactate utilization [297]. In breast cancer, similar lactate crosstalk exists between CAFs and tumor cells [298]. CAFs supply amino acid-carrying extracellular vesicles (EVs) to support central carbon metabolism in nutrient-deprived tumor cells and secrete stimulatory factors such as VEGF, PDGF, and FGF to stimulate angiogenesis [299], maintain tumor cell growth, and enhance mitochondrial and OXPHOS levels, promoting tumor cell oxidative potential, self-renewal capacity, and drug metabolism, thereby increasing drug resistance [300]. Additionally, CAFs enhance tumor tissue stiffness to increase drug resistance. For example, increased breast cancer stroma stiffness can activate Yap in CAFs, increasing periostin secretion, promoting stroma cross-linking, further enhancing stiffness, and increasing drug delivery difficulty. Increased periostin secretion also activates the Integrin/FAK/ERK/Cdc42/Rac1 mechanotransduction pathway, promoting collective tumor cell invasion [301]. CAFs can also increase cancer stem cell stemness, remodel the extracellular matrix to create physical barriers against chemotherapeutic drugs [302], and secrete soluble factors for paracrine communication with surrounding stromal cells, promoting resistance. For instance, a specific CAF subset (CD10 + GPR77 + CAF) in breast cancer is associated with prognosis and chemotherapy sensitivity, potentially maintaining cancer stem cell stemness, enhancing immune suppression, and reducing immunotherapy efficacy through IL-6 and IL-8 secretion to remodel the TME [303]. As the most plastic stromal cells, different CAF subtypes interact with tumor cells through various metabolic reprogramming pathways and TME remodeling, providing energy during nutrient deprivation, maintaining cancer stem cell stemness, and repairing chemotherapy-induced damage to tumor cells, thus enhancing drug resistance and reducing drug efficacy. Therefore, targeting CAF metabolic pathways, such as glycolysis, altering CAF phenotypes, or blocking their energy crosstalk with tumor cells through strategies like CAF depletion and reprogramming provides new insights to reduce tumor cell drug resistance and improve anti-tumor drug efficacy [304]. In the TME, tumor cells can communicate through the vasculature. Tumor cells and tumor-associated ECs (TEC) can directly interact within the tumor vasculature, influencing malignant angiogenesis, tumor cell proliferation, and invasion capabilities [305]. In tumor vasculature, TECs are located on the luminal side, regulating angiogenesis and permeability, and detecting circulating pathogens (Fig. 3). Tumor cells can generate high interstitial fluid pressure, exacerbating vascular collapse and fluid leakage, worsening hypoxia, and nutrient deprivation in the TME, affecting energy crosstalk between tumor cells and ECs [306]. ECs rely on glycolysis for energy, so metabolic reprogramming of tumor-associated ECs also affects tumor angiogenesis. For example, in breast cancer, hypoxia not only stimulates TEC glycolysis but also enhances fructose utilization and activates TEC AMPK signaling, enhancing mitochondrial activity, invasion, and metastasis, promoting tumor endothelial generation [307, 308]. The poor efficacy of anti-angiogenic drugs like sorafenib and lenvatinib in first-line treatment of advanced breast cancer suggests that targeting fructose metabolism in TECs could enhance anti-angiogenic therapy efficacy [309]. Key Mechanisms of Metabolic and Immune Modulation in the Tumor Microenvironment. A Nerve cells secrete norepinephrine, activating β-adrenergic receptors and triggering the PI3K/AKT/mTOR pathway. This enhances glucose metabolism and lactate production, with mTOR and HIF-1α upregulation intensifying inflammation and metabolic dysfunction, contributing to drug resistance. B In the tumor vascular niche, endothelial cells under hypoxic conditions regulate angiogenesis via VEGFR2, FGFR, and other receptor-mediated pathways. This involves glycolysis, degradation of the basement membrane, endothelial progenitor cell migration, and the formation of abnormal blood vessels, promoting tumor vascularization and resistance to therapy. C Bacterial metabolism, particularly lactate production and microenvironment acidification, modulates the activity of tumor-associated immune cells, such as TAMs, DCs, and T cells. This induces cytokine release and inflammatory responses, further enhancing tumor cell resistance TECs directly contact immune cells in the vasculature, acting as the first line of defense in immunotherapy, and playing a crucial role in drug penetration and immunotherapy. Therefore, combining anti-tumor angiogenesis targeting TECs with immunotherapy is essential to improve drug penetration, recruit tumor-killing immune cells, and enhance immunotherapy efficacy. Tumor neovasculature in the TME usually lacks pericytes, with TECs releasing large amounts of VEGF to recruit immunosuppressive cells and reduce cytotoxic T cell activity, forming an immunosuppressive microenvironment that leads to immune escape and reduces immunotherapy efficacy [310]. The high permeability, hypoxia, and VEGF production of tumor neovasculature accelerate tumor growth. For example, in TNBC, TECs upregulate Fas ligand expression to induce T cell apoptosis, limiting T cell infiltration and causing immune escape. TECs also play crucial roles in repairing chemotherapy-induced tumor cell damage and promoting chemotherapy resistance [311]. After chemotherapy stimulation, TECs upregulate ABCB1 protein to accelerate drug efflux, reducing damage to tumor cells and promoting resistance. For example, in breast cancer, paclitaxel induces cancer cells to secrete large amounts of IL-8, stimulating increased ABCB1 protein expression in TECs, and increasing chemotherapy resistance [312]. Due to cancer-type heterogeneity in tumor angiogenesis, pan-cancer treatments targeting tumor endothelium have limited efficacy. In TNBC, cancer stem cells specifically express tumor endothelial marker TEM8 (Tumor Endothelial Marker 8), enhancing cancer stem cell stemness and vasculogenic mimicry through the RhoC/ROCK1/SMAD5 signaling pathway, increasing drug resistance and nutrient supply. Therefore, targeting TEM8 is significant for alleviating TNBC resistance and enhancing chemotherapy efficacy [313]. Tumor-associated lymphatic ECs in the TME have two differentiation lineages: lymphangiogenesis and antigen presentation. Hypoxia and VEGF promote lymphangiogenesis, while antigen-presenting lymphatics specifically express the anti-inflammatory factor TSC22D3, inhibiting NF-κB nuclear translocation and DNA binding and mediating HIF1-α degradation, enhancing anti-tumor immunotherapy efficacy [314]. However, in breast cancer, paclitaxel inhibits LEC migration and branching by inducing a non-Akt phosphorylation autophagy pathway, promoting lymphatic metastasis of tumor cells [315]. Fibroblasts, are highly plastic stromal cells, derived from bone marrow-derived mesenchymal stem cells (MSCs) with strong clonogenic and self-renewal abilities. Interacting with tumor cells, they transform into tumor-associated stromal cells (TA-MSCs), acquiring tumor-promoting phenotypes and playing crucial roles in immune regulation, therapeutic resistance, and extracellular matrix regulation in the inflammatory TME [316]. During interaction with breast cancer cells, MSCs promote angiogenesis by directly secreting pro-angiogenic factors. Their exosomes stimulate cancer cells to secrete VEGF, activating the ERK1/2 signaling pathway, stimulating angiogenesis, reducing central tumor necrosis, and promoting tumor growth. Additionally, during tumor progression, MSCs survive through autophagy, releasing anti-apoptotic and pro-survival factors, reducing tumor cell apoptosis, and maintaining continuous proliferation [317, 318]. MSCs promote the formation of an immunosuppressive microenvironment and immune escape by secreting various cytokines like IL-1α, TGF-β, HGF, IFN-γ, and TNF-α, interacting with immune cells to mediate extensive immunosuppression. For example, in breast cancer, MSCs induce CD4 + T cell transformation from Th1 to Th2 phenotype, reducing IFN-γ secretion and increasing IL-4 secretion, reducing the activation and killing of anti-tumor immune cells. MSCs recruit myeloid macrophages through the CCL2 pathway, enhancing immunosuppression [319]. However, research shows that IL-15 secreted by MSCs upregulates PD-1 in MSCs, providing potential for enhancing PD-1 immunotherapy efficacy [320]. MSCs have low immunogenicity, superior migration characteristics to immune cells, and stronger migration abilities to inflammation or injury sites [321], suggesting MSCs as anti-tumor drug carriers for targeting tumor cells and enhancing immunotherapy efficacy [322, 323]. MSCs mediate external resistance mechanisms in breast cancer by directly promoting ABC transporter activation, enhancing drug efflux, increasing tumor cell survival rates, reducing drug sensitivity, and promoting chemotherapy resistance [323]. Physical contact with breast cancer cells activates non-receptor tyrosine kinase c-Src and downregulates tumor suppressor gene PTEN, mediating trastuzumab resistance through the PI3K/AKT pathway. Additionally, cisplatin-exposed MSCs produce polyunsaturated fatty acids to reduce chemotherapy toxicity. Utilizing MSCs’ extensive immunosuppression and strong tumor cell tropism, modifying them as immunosuppressant carriers provides new strategies to enhance immunotherapy efficacy and improve breast cancer treatment and resistance [324]. Stromal cells engage in energy crosstalk with tumor cells through various metabolic pathways, but targeting stromal cells alone presents limitations due to cancer-type heterogeneity. In breast cancer, targeting stromal cells with anti-angiogenic drugs like bevacizumab and ramucirumab often yields poor results. Therefore, blocking energy crosstalk pathways between stromal cells and tumor cells or their glycolysis may significantly enhance anti-angiogenic drug efficacy, reduce tumor energy supply, and decrease drug metabolism and stimulation of cancer stem cell stemness, thereby reducing resistance and improving drug efficacy. From a metabolic reprogramming perspective, personalized interference or blocking of energy crosstalk between stromal cells and tumor cells provides new insights to improve tumor resistance, enhance chemotherapy drug utilization, and increase the efficacy of stromal-targeted drugs such as anti-angiogenic drugs. Tumor-associated neuronal metabolic reprogramming on drug resistance The nervous system constitutes a vital element of the cellular microenvironment, extensively distributed and systematically regulating bodily functions, whether in health or disease. Recent studies have revealed a close relationship between neuro-tumor crosstalk and the development and progression of tumors. As an integral part of the TME, tumor-associated nerve fibers primarily exert neural control via neurotransmitters, neuroactive substances, and electrical signals [290]. These regulatory signals from nerves can foster malignant behavior in tumor cells, assist in the formation of an immunosuppressive microenvironment, and consequently drive tumor cell proliferation, invasion, metastasis, and immune evasion. Concurrently, tumor cells are capable of recruiting and modulating nerve fibers to create a microenvironment more conducive to their survival. Thus, these factors suggest that neuro-tumor crosstalk underlies the current challenges in tumor treatment resistance [325]. It is widely accepted that the innervation of breast cancer originates from peripheral nerves, with sympathetic, parasympathetic, and sensory nerve fibers being the principal components of its microenvironment. Pathological evidence indicates that the density of nerve fibers in breast cancer tissues is higher than in normal breast tissues or benign breast tumors, and this density correlates positively with tumor aggressiveness [326, 327]. This observation suggests that breast cancer has the potential to promote the infiltration of nerve fibers within the tumor, a capacity that escalates with the malignant progression of the disease [328]. Nerve fibers infiltrating breast cancer tissues typically manifest in two forms: nerve control (tumor neural infiltration) and perineural invasion. Nerve control (tumor neural infiltration) Nerve control refers to the active recruitment of nerves by the tumor into the TME, promoting nerve branching within the TME, thereby enhancing the malignant behavior of tumor cells [329]. Breast cancer cells secrete various cytokines, including neurotransmitters and vascular growth factors, which facilitate nerve fiber growth and extension. These recruited nerve fibers actively contribute to the progression of breast cancer. Specifically, the recruited sympathetic nerves predominantly accelerate tumor progression and growth, while parasympathetic nerves exert opposite effects. Sensory nerves infiltrating the tumor tissue generally inhibit the progression of breast cancer. A series of studies have demonstrated that nerve fibers involved in nerve control regulate tumor progression both directly, through interactions with tumor cells and indirectly, through interactions with other cells within the TME (Fig. 3), such as immune cells and stromal cells [330]. Direct interaction between nerves and tumor cells Tumor cells are primarily regulated by neurotransmitters from the autonomic and sensory nerves. The hyperactivity of sensory nerves frequently promotes the formation of an immunosuppressive microenvironment in their target areas, which in turn fosters tumor cell proliferation and metastasis. Sympathetic nerves accelerate tumor progression and growth, while parasympathetic nerves have the opposite effect. Research conducted by Veena Padmanaban et al. shows that neuropeptide P (SP) released by sensory neurons can activate TLR7 in tumor cells through intercellular interactions [326]. The activation of TLR7 triggers downstream NFκB signaling, which promotes c-Myc expression, inducing cell proliferation, invasion, and anti-apoptotic capabilities [272]. Upregulation of the Myc signaling pathway reprograms tumor cell metabolism, enhancing their proliferation, metastasis, and invasion capacities [331]. In the low-glucose environment within tumors, nociceptive neurons secrete calcitonin gene-related peptide (CGRP), which activates Rap1 in tumor cells to block the interaction between Raptor and mTOR, promoting protective autophagy under glucose-deficient conditions. Elevated ROS levels in tumor cells activate the JNK-c-Jun pathway, which subsequently activates nerve growth factor (NGF) transcription, promoting CGRP secretion and creating a vicious cycle between tumor cells and nociceptive neurons. Current research predominantly suggests that sensory neurons, particularly nociceptive neurons, generally promote tumor proliferation and metastasis [326, 327]. However, during the progression of breast cancer, sensory nerves can also exert inhibitory effects. Research by Nuray Erin [332] revealed that capsaicin-sensitive sensory nerves could release substance P, producing bioactive anti-tumor peptide fragments that enhance the anti-tumor immune response and inhibit breast cancer progression. Similar phenomena were observed in studies by Noémi Bencze [333] et al. This suggests that sensory neurons exert bidirectional regulatory effects during the overall progression of breast cancer. Nonetheless, the molecular mechanisms by which they regulate tumor cell metabolism and influence tumor cell biological behavior require further investigation. The progression of breast cancer is also closely related to the autonomic nervous system [334–336]. The autonomic nervous system regulates tumor cells through sympathetic (adrenergic) and parasympathetic (cholinergic) responses. Sympathetic nerves in the breast cancer microenvironment secrete adrenaline (E) and norepinephrine (NE), which act directly on tumor cells by binding to adrenergic receptors (ARs) [337]. ARs are primarily divided into α and β receptor subtypes. It is generally believed that E and NE exert different effects on breast cancer progression through α or β ARs, with overactivation of α-AR promoting breast cancer progression. Research shows that when α2-AR is activated by the α2-AR agonist dexmedetomidine, the phosphorylation level of its downstream Erk signaling pathway increases [338], upregulating the non-oxidative PPP, promoting ribose synthesis, and providing sufficient repair materials for DNA damage caused by chemotherapy. This process enhances the tumor’s anti-apoptotic capacity, leading to multidrug resistance (MDR) in breast cancer [339]. However, current research on the role of β-AR in breast cancer remains inconclusive, with studies reporting both tumor-promoting and anti-tumor effects. Under chronic stress, overactivation of β2-AR downregulates peroxisome proliferator-activated receptor γ (PPARγ) [340], continuously activating the expression of downstream lipid uptake-related genes CD36 and FABP4, promoting the absorption of exogenous fatty acids by breast cancer cells and mediating their proliferation and metastasis [341]. Research by Sarah J. Creed et al. found that β2-AR released by sympathetic nerves can regulate Src in breast cancer cells, upregulating glucose metabolism and promoting the growth of invasive pseudopodia in tumor cells, thereby enhancing breast cancer cell invasion and metastasis [342, 343]. Additionally, in breast cancer, β-AR forms a positive feedback loop with HER-2, where stimulation of β-AR by catecholamines (Epi) activates the downstream PI3K/Akt/mTOR signaling pathway, mediating trastuzumab resistance, which can be reversed by β-blockers [344]. The application of β2-AR blockers can inhibit breast cancer progression by downregulating hexokinase-2 expression and glucose metabolism in breast cancer cells [345]. Several retrospective clinical studies have also shown that β2-AR blocker treatment can reduce the risk of metastasis in breast cancer patients [346–348]. However, research by Lucía Gargiulo et al. indicates that low concentrations of Epi promote the proliferation of MCF7 and MDA-MB 231 cells, while the β2-AR agonist isoproterenol inhibits the proliferation of both cell lines [349]. Other studies have suggested that β2-AR agonists can inhibit the proliferation and DNA synthesis of TNBC cells [350, 351]. In conclusion, sympathetic nerves primarily promote the progression of breast cancer and may lead to the development of drug-resistant phenotypes. Nonetheless, some studies on AR have shown contradictory results, which might be due to interactions among different components within the TME. The specific mechanisms involved still require further research. In the TME, the parasympathetic nervous system typically modulates disease progression through the release of acetylcholine (Ach), with its effects on tumors varying across different tissue types. In gastric cancer, acetylcholine promotes tumor progression by activating the EGFR-ERK-AKT signaling pathway via the M3R receptor on tumor cells [352, 353]. Conversely, in pancreatic ductal adenocarcinoma, acetylcholine binds to the M1 receptor and inhibits tumor growth by downregulating the MAPK/EGFR and PI3K/AKT pathways [354, 355]. In breast cancer, Ach primarily influences tumor cell behavior through nicotinic (nAChR) and muscarinic receptors (mAChR) [356, 357]. The inhibitory effect of the parasympathetic nervous system on breast cancer is largely mediated by M1-AChR [358]. However, most studies indicate that AChR activation contributes to the progression of breast cancer. For example, in the MCF10A and MCF7 cell lines, nicotine-induced activation of nAChR enhances the activity of downstream protein kinase C (PKC) and initiates a signaling cascade involving PKC and Cdc42 [359]. As a small GTPase, Cdc42 regulates nucleotide metabolism in tumor cells by controlling guanine nucleotide exchange factors that mediate GDP/GTP exchange [360]. Consequently, nAChR activation may promote the growth [361] and migration [359] of breast epithelial and tumor cells by modulating nucleotide metabolism. Additionally, mAChR activation can induce the MAPK/ERK pathway, which is implicated in the regulation of breast cancer cell growth and proliferation [362]; hyperphosphorylation of MAPK/ERK in breast cancer cells is associated with resistance to HER2-targeted therapies, including tucatinib and neratinib. Overall, the parasympathetic nervous system appears to predominantly facilitate tumor progression, although the precise mechanisms by which it influences breast cancer progression and drug resistance via metabolic pathways require further investigation [363, 364]. Interaction between nerves and other cells in the TME In recent years, growing evidence suggests that the interaction between the nervous system and angiogenesis plays a critical role in tumor development. Sympathetic/β-adrenergic signaling transmitted to the blood vessels and lymphatic vessels of tumors contributes to metastasis, with the release of sympathetic neurotransmitters closely linked to neovascularization. Neurotransmitters such as E, NE, serotonin (5-HT), and glutamate can all promote tumor angiogenesis [365, 366]. Research by Ali H. Zahalka [367]et al. demonstrated that adrenergic signaling through COA6 controls aerobic metabolism in prostate vascular ECs, thereby promoting angiogenesis in prostate cancer. Meanwhile, β2-AR gene knockout significantly inhibited vascular growth in mouse prostate tumors [368]. The activation of AchR can also promote VEGF synthesis by increasing arginine metabolism in M1 macrophages, thereby fostering tumor angiogenesis [369]. Sympathetic, parasympathetic, and sensory nerves regulate tumor progression by modulating tumor immunity, with the sympathetic nervous system involved in regulating almost all immune cells. In pancreatic cancer, the sympathetic nervous system regulates the TME’s immune response through β-adrenergic signaling. Activation of β-AR by catecholamines promotes ADRB1 expression and advances CD8 + T cell exhaustion through the cAMP-CREM pathway [370]. Previous studies have shown that chemotherapy can stimulate neurogenesis, neurite outgrowth, and neurotransmitter release, enhancing sympathetic signaling, which may mediate resistance to anthracycline chemotherapy in TNBC [347, 371]. Shutting Zuo et al. found that inhibiting nerve growth factor expression in tumor cells after chemotherapy can reduce sympathetic proliferation, increase immune-stimulating cell infiltration in the TME, and decrease the proportion of immunosuppressive cells [372]. In summary, sympathetic nerves can promote tumor progression by inhibiting anti-tumor immunity. β-Endorphin neurons exhibit anti-tumor activity by activating parasympathetic and anti-sympathetic nerves. Specific nerve activity blockers or stimulators, such as propranolol, may be promising drugs for tumor treatment. However, the mechanisms by which nerve infiltration regulates tumor progression in breast cancer are not yet fully understood, and the relationship between nerve infiltration and tumor cell metabolism requires further study. Perineural Invasion (PIN) PIN primarily refers to the invasion of local nerves by tumors, wherein malignant cells encircle or invade nerve bundles and extend along them [330]. PIN has been reported in various solid tumors and is often associated with an invasive phenotype and poor prognosis in patients [373–375]. To date, reports on PNI in breast cancer are scarce, and its incidence is yet to be conclusively determined [376, 377]. PIN formation is influenced by various regulatory factors. Research by Bing Han et al. found that increased matrix stiffness can induce tumor cell metastasis and NGF expression through the integrin β1-FAK-YAP signaling pathway, ultimately promoting PIN in breast cancer [378]. NGF can inhibit neuronal apoptosis through the p-PI3K/Akt signaling pathway [379] and promote growth by binding to tropomyosin receptor kinase A and activating the PI3K/AKT, phospholipase C-γ, and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways [380]. However, the mechanisms of PNI-related drug resistance in breast cancer have not yet been studied, and its prognostic significance remains inconclusive. Therefore, further research is necessary to clarify the mechanisms and define the role of PIN in breast cancer. Bacterial metabolic reprogramming on drug resistance Bacteria are distributed throughout the human body, with approximately 90% concentrated in the gastrointestinal tract [381]. The composition of the gut microbiota varies according to the host’s physiological state [382] and living environment [383]. In pathological conditions, inflammation [384], immune regulation [385], and metabolic disorders [386] in the human body are closely related to the imbalance of the gut microbiota. The chaotic vasculature, rich nutrients, and hypoxic conditions of the TME provide favorable conditions for the growth of tumor-associated bacteria [387]. Intratumoral bacteria are considered part of the tumor tissue. Due to the high heterogeneity of the TME, the structure, type, and abundance of tumor-associated bacteria vary among different tumors, different subtypes of the same tumor, and different stages of the same subtype [388]. For example, Helicobacter, Fusobacterium, and Clostridium are significantly enriched in pancreatic cancer [389]; Burkholderiales, Pseudomonas, Xanthomonadales, and Bacillus are significantly enriched in hepatocellular carcinoma [390]; Nuciferocarcinus and enterotoxigenic Bacteroides fragilis are significantly enriched in CRC [391]; in breast cancer, tumor-associated bacteria are most enriched, predominantly including Streptococcus agalactiae, Lactobacillus iners, Corynebacterium, and Fusobacterium nucleatum, and their abundance varies among different subtypes and stages of the same subtype of breast cancer [392, 393]. Intratumoral bacteria in breast cancer may originate from adjacent organs, breast skin, or the blood circulation of the gut microbiota [394]. Through the rich vascular network within the tumor, these bacteria enter the tumor tissue from damaged intratumoral blood vessels [395]. Therefore, the intratumoral microbiota in breast cancer is influenced to a certain extent by the gut microbiota, whose ecological diversity, enrichment levels, and metabolite levels can affect the distribution and enrichment of intratumoral bacteria. The gut microbiota can influence the risk and prognosis of breast cancer by regulating hormone levels and inflammation in the body [396]. The gut microbiota is easily affected by various drugs and can also influence the efficacy of chemotherapy and immunotherapy. For example, Bacteroides fragilis in the gut microbiota is enriched in the tumor tissue of breast cancer patients who do not respond to chemotherapy. Through interaction with NOD1 [397], highly expressed by tumor stem cells, Bacteroides fragilis promotes docetaxel chemotherapy resistance. The combination of the antibiotic metronidazole, the NOD1 inhibitor Nodinitib-1, and docetaxel can effectively inhibit the proliferation and stemness of breast tumor cells, providing a new “triple therapy” to reverse docetaxel resistance in breast cancer. Targeting the gut microbiota to reverse chemotherapy resistance offers a new direction for improving chemotherapy sensitivity. Intratumoral bacteria often exist in the cytoplasm of immune cells and tumor cells in the form of cell wall defects. The bidirectional interaction between intratumoral bacteria, their metabolites, and the TME can stimulate immune cell polarization into different states (Fig. 3). Tumor cells also exhibit different growth or inhibitory states. Therefore, the interaction between intratumoral bacteria, tumor cells, and immune cells can significantly impact tumor metastasis, chemotherapy, immunotherapy efficacy, and treatment resistance [394]. In the immune microenvironment of breast cancer, intratumoral bacteria, and their metabolites exhibit a dual role in antitumor immune regulation. On one hand, they can enhance antitumor immune efficacy by activating the STING signaling pathway, enhancing T cell antitumor activity, stimulating tertiary lymphoid organ formation, and enhancing antigen presentation [394]. On the other hand, they can reduce antitumor immune responses by upregulating ROS, promoting T cell inactivation, creating an inflammatory microenvironment, and enhancing immune suppression. For example, Escherichia coli in the intratumoral microbiota of breast cancer can cause immune suppression by reducing anti-inflammatory cytokine production and increasing pro-inflammatory cytokine production. It can also enhance immune suppression by reducing intratumoral T cells and M1 macrophages and increasing M2 macrophages, leading to immune escape [398, 399]. In TNBC, Clostridium-related metabolites such as TMAO not only activate PEKB protein on the endoplasmic reticulum of breast cancer cells, inducing ferroptosis, but also release inflammatory cytokines into the TME, recruiting CD8 + T cells and enhancing immune infiltration and functional activation, thereby improving immunotherapy efficacy [400]. In recent years, with the increase in research and clinical trials targeting intratumoral bacteria and their metabolites, the mechanisms by which they enhance immunotherapy efficacy have become increasingly clear. Given the diversity of intratumoral bacteria in breast cancer, there are many ways to regulate immune cells. Intratumoral bacteria and their metabolites can directly participate in the regulation of immune cell activity [401]. For example, a short-chain fatty acid metabolite, especially pentanoate, can enhance the antitumor activity of CD8 + T cells and improve the efficacy of immune checkpoint inhibitors by affecting CD8 + T cell energy metabolism and EMT-enhanced epigenetic reprogramming. This can be used to improve the efficacy of CAR-T therapy [402]. This suggests that some tumor metabolites may be used as microbial factors to enhance antitumor immunity in the future. Treg cells in the TME negatively regulate the immune-killing effects of various T cell subsets. Based on their affinity for energy substrates lactate and glucose, Treg subsets are divided into glucose-affinitive and lactate-affinitive subsets. Lactate-affinitive Treg subsets have stronger immune suppression functions [403, 404]. The generation of lactate in breast cancer, apart from the Warburg effect of tumor cells, also originates from intratumoral bacteria such as Lactobacillus iners. This enhances the immune suppression of Treg cells, weakening the tumor-killing ability of CD8 + T cells [405]. Therefore, targeting intratumoral lactate-producing bacteria and using nano cloak technology that carries metabolites enhancing CD8 + T cell killing ability can reduce lactate production, lower Treg cell immune suppression, enhance CD8 + T cell antitumor capacity and improve immunotherapy efficacy [406]. Macrophages, being the most plastic immune cells, are easily polarized to the M2 phenotype in the immunosuppressive TME, limiting their tumor-killing ability [407]. Adoptive cell therapy utilizes the immunogenicity of intratumoral bacteria in breast cancer to attach them to macrophages, enhancing macrophage immunogenicity and continuously stimulating them, resisting M2 polarization induced by the TME, and potentially repolarizing M2 macrophages back to M1 macrophages. Remodeling the immune microenvironment and enhancing macrophage tumor-killing ability is crucial for improving immunotherapy efficacy [408]. Intratumoral bacteria can enhance the stemness of tumor stem cells and drug resistance of tumor cells through multiple metabolic pathways, promoting cancer progression, metastasis, and drug resistance [409]. For example, in CRC, Fusobacterium nucleatum accelerates fatty acid metabolism, reducing fatty acid accumulation in tumor stem cells, promoting self-renewal, and increasing fatty acid levels in non-tumor stem cells, accelerating their transformation into tumor stem cells [410]. Intratumoral bacteria can also accelerate the metabolism of chemotherapeutic and immunotherapeutic drugs, promoting drug resistance. For example, intratumoral Mycoplasma produces microbial cytidine deaminase, accelerating the metabolism of the chemotherapeutic drug gemcitabine into the inactive 2′2-difluorodeoxyuridine, promoting gemcitabine resistance [411]. Furthermore, intratumoral bacteria can promote the lactic acidification of the TME, enhancing the oxidative stress response of tumor cells to radiotherapy and chemotherapy by replacing glucose with lactic acid in energy cycling, increasing tumor cell invasiveness [412]. For example, intratumoral Lactobacillus iners enhances L-lactate metabolism in breast cancer, altering lactate signaling pathways and promoting tumor resistance. Targeting lactate-related intratumoral bacteria may reverse tumor resistance and provide new targets for immunotherapy [413, 414]. Studies have shown that the use of antibiotics can reduce the occurrence of drug resistance to a certain extent [414]. Precise targeting of specific intratumoral bacterial populations and combining them with chemotherapeutic drugs may provide new ideas for improving chemotherapy sensitivity. The diversity of intratumoral bacteria in breast cancer, and their interaction with immune cell populations, exhibit a dual role in immune regulation within the breast cancer TME. Some intratumoral bacteria in breast cancer can promote drug resistance and tumor metastasis [392]. 16 S rRNA sequencing analysis may become a future method for identifying microbiomes in cancer. This technology has revealed that the microbial composition in tumor tissues differs from that in healthy controls in various cancers [390]. Currently, multiple intratumoral bacterial adjuvant therapy strategies exist. For example, engineered bacteria can precisely deliver drugs, directly promote tumor cell apoptosis, and reduce immune escape [415]; fecal microbiota transplantation, though still in its infancy, has been widely used in treating gastrointestinal diseases [416]; nano-antibacterial materials utilize the EPR effect to target cancer cells, reduce immune escape, and avoid toxicity to the gut microbiota [417]. Identifying the distribution of intratumoral bacteria, and comparing it with healthy tissues, targeting immunosuppressive intratumoral bacteria, and exploring tumor microbiome-based interventions combined with chemotherapy or immunotherapy can improve treatment sensitivity and reduce resistance, providing new approaches for breast cancer prevention and improving cancer cure rates. Systemic metabolic reprogramming on drug resistance The high incidence of cancer today is closely linked to lifestyle factors such as poor diet, lack of physical activity, and obesity, particularly in cancers such as colorectal, breast, endometrial, and pancreatic cancers. Recent studies have demonstrated that lifestyle interventions, including dietary modifications (e.g., fasting and ketogenic diets), increased physical activity, and weight control, can significantly influence tumor metabolism and thus affect cancer development and treatment. Fasting and ketogenic diets can inhibit cancer cell growth through a variety of metabolic pathways, while exercise and weight control improve the metabolic environment and immune function, suppressing tumor progression. Moreover, these interventions can enhance the efficacy of conventional cancer treatments and improve patients’ quality of life. This chapter aims to explore the mechanistic roles of fasting, exercise, and obesity in tumor metabolism and their application in cancer prevention and treatment, providing a theoretical basis and practical guidance for clinical interventions. Fasting and tumor metabolism Nutrients play a critical role in regulating various physiological processes, and their primary source is diet. In the TME, cancer cells undergo “metabolic reprogramming” to meet their unique metabolic needs, thereby affecting patient nutritional status, treatment outcomes, and ultimately tumor progression. Numerous studies have shown that energy restriction can inhibit tumor growth and enhance the efficacy of treatments such as radiotherapy and chemotherapy. Thus, diet serves as both a key factor in cancer incidence and an important modulator of cancer treatment. Dietary interventions have demonstrated the potential to enhance anticancer therapies and improve prognosis [418–420]. Targeted dietary adjustments for cancer patients can alter the tumor metabolic microenvironment, which, when combined with standard therapies, can ultimately improve treatment outcomes. In this section, we describe fasting (including complete fasting, fasting-mimicking diets, and intermittent fasting) and the ketogenic diet. Fasting Fasting therapy aims to inhibit tumor growth and enhance treatment efficacy by restricting food or specific nutrient intake [421]. More than a century ago, studies demonstrated that fasting and caloric restriction have significant antitumor effects in animal models [422]. Recent research has shown that fasting can increase the sensitivity of cancer cells to chemotherapeutic agents [423]. Fasting therapies primarily include complete fasting, fasting-mimicking diet (FMD), and intermittent fasting (IF). Complete fasting, which involves consuming only water, typically requires at least 48 h to demonstrate efficacy, making it challenging for most patients to adhere to. To address this issue, Professor Valter Longo proposed FMD, which mimics the fasting state through a periodic dietary regimen, allowing patients to gain the benefits of fasting without experiencing significant hunger [423]. FMD has been shown to lower glucose and insulin-like growth factor-1 (IGF-1) levels, reshape systemic immune function, and enhance antitumor immune responses, particularly when combined with chemotherapy and immunosuppressants, leading to significant improvements in treatment outcomes [424–426]. Intermittent fasting, on the other hand, involves alternating periods of fasting and normal eating to achieve metabolic modulation and is considered relatively safe. Studies indicate that IF not only inhibits tumor growth by altering energy metabolism in cancer cells but also improves immune system function, promoting antitumor immune responses, and thereby holds considerable promise in cancer immunotherapy [427–431]. For example, one study demonstrated that CD8 + T cell infiltration increased by 40% in breast cancer-bearing mice following IF, significantly enhancing antitumor effects. Alternate-day fasting is a common IF strategy that has also been found to improve treatment outcomes during chemotherapy [432]. In addition to antitumor effects, IF has shown potential in alleviating metabolic diseases, reducing insulin resistance, and promoting weight loss [433]. As an emerging cancer intervention strategy, fasting therapy modulates the metabolic microenvironment and immune responses, exerting profound effects on tumor growth, progression, and patient survival. Furthermore, the ability of fasting to positively regulate the tumor immune microenvironment highlights its potential role in cancer immunotherapy. Ketogenic diet The ketogenic diet (KD) has emerged as a novel cancer metabolic therapy due to its unique ability to shift energy metabolism from glucose to fat, targeting the metabolic vulnerabilities of cancer cells, which are less capable of utilizing ketone bodies compared to normal cells. KD is a dietary regimen characterized by high fat, low carbohydrate, and moderate protein intake [434]. By strictly limiting carbohydrate intake, KD simulates a state of starvation, forcing the body to rely on fat as the primary energy source. This metabolic shift from glucose to fat produces ketone bodies, which serve as an energy source for normal cells, whereas cancer cells cannot effectively utilize ketone bodies, thus inhibiting tumor proliferation [435]. Ketone bodies, as products of fat metabolism, not only provide energy but also exhibit antitumor effects through multiple mechanisms, including modulating immune responses, reducing inflammation, and enhancing oxidative stress. Several studies have shown that KD can inhibit tumor growth [436], prolong patient survival [437], and improve quality of life [438]. In terms of tumor metabolic regulation, KD first reduces insulin and IGF-1 levels by strictly limiting carbohydrate intake, thereby inhibiting the PI3K)/ Akt/ mTOR signaling pathway, reducing glucose uptake, and ultimately inhibiting tumor growth [439]. Furthermore, the reduction in blood glucose and increase in ketone levels inhibit the expression of carbohydrate response element-binding protein (ChREBP), which in tumor cells promotes aerobic glycolysis and cell proliferation through p53 inhibition. KD suppresses ChREBP expression, thereby inhibiting tumor cell proliferation [440]. The accumulation of ketone bodies also reduces the activity of key metabolic enzymes such as hexokinase and lactate dehydrogenase and decreases the expression of glucose transporter-1, further limiting tumor growth [441]. Moreover, KD reduces glucose availability, inhibits aerobic glycolysis, and downregulates the pentose phosphate pathway, leading to decreased tumor cell proliferation and an imbalance in intracellular antioxidant systems. For example, studies have shown that KD reduces NADPH production in tumor cells, thereby inducing oxidative stress and causing tumor cell damage [442]. KD has demonstrated significant antitumor effects in a variety of cancers, including breast, lung, gastric, and colorectal cancers [443–446]. Although some potential side effects, such as gastrointestinal disturbances and hypoglycemia, have been reported, these are generally mild [447]. Additionally, compared to other treatment modalities, KD is associated with high safety, low cost, and greater acceptability among cancer patients. In summary, while current evidence indicates that KD has significant antitumor potential, its mechanisms remain complex and warrant further investigation. Future research should focus on developing individualized KD regimens tailored to specific cancer types and in conjunction with existing conventional therapies to maximize therapeutic effects. Only when dietary plans are matched to the specific conditions of cancer patients can KD achieve optimal outcomes in cancer prevention and treatment. Exercise and tumor metabolism Studies have indicated that approximately 25% of cancers are closely related to obesity and sedentary lifestyles [448], particularly cancers such as colorectal, breast, and endometrial cancers. Obesity and sedentary lifestyles are associated with an increased risk of these malignancies. In this context, exercise plays a crucial role in maintaining physiological homeostasis and cancer prevention, emerging as a key area of interest in cancer research. Through diverse mechanisms, exercise can effectively influence cancer initiation, progression, and treatment. As a non-pharmacological adjuvant therapy, exercise significantly improves the physical fitness and quality of life of cancer patients, particularly for colorectal, breast, and endometrial cancers. For instance, research found that regular aerobic exercise could reduce colorectal cancer risk by approximately 20-30%. Among breast cancer patients, appropriate exercise has been shown to significantly enhance quality of life and prognosis. Exercise modulates the TME, profoundly impacting tumor cell metabolism and growth. Specific mechanisms include increased blood flow and oxygen delivery to tumor tissues, enhanced immune cell (e.g., T cells and natural killer cells) infiltration, and inhibition of tumor growth by altering metabolite concentrations such as lactate and glucose. Exercise can convert “cold” tumors into “hot” tumors, thereby making the TME more conducive to immune cell infiltration and activation [449]. Exercise also modulates key metabolite concentrations, thereby regulating tumor cell energy metabolism and inhibiting proliferation [450]. Additionally, exercise plays a critical role in regulating the immune system. Studies have shown that exercise increases the number and activity of anticancer immune cells, such as CD8 + T cells, thereby enhancing their cytotoxicity against tumor cells [451]. Exercise also induces the release of immune regulatory factors such as IL-6 and IL-7, promoting the proliferation, differentiation, and infiltration of natural killer (NK) cells and T cells [452, 453]. Increased NK cell quantity and activity are essential for enhancing immune surveillance and clearing tumor cells. Exercise further induces metabolic reprogramming in tumor cells, reducing their reliance on aerobic glycolysis and thereby inhibiting proliferation. Goh et al. found that long-term exercise significantly reduces the concentrations of growth-promoting factors such as insulin and IGF-1, thereby suppressing tumor growth [454]. Moreover, exercise significantly impacts cancer metabolic resistance and clinical outcomes. Exercise alters tumor cell metabolic pathways, reducing their dependence on glycolysis, thereby mitigating tumor resistance. For instance, exercise enhances mitochondrial oxidative phosphorylation, decreasing tumor cell reliance on glycolysis and reducing resistance to certain drugs. Exercise also increases the sensitivity of tumor cells to chemotherapy and targeted therapies by modulating the immune system and metabolic microenvironment, thus improving treatment efficacy. Complex interactions exist between immune cell activation and metabolic alterations within the TME. These interactions enhance sustained immune cell activation and their antitumor capabilities, effectively inhibiting tumor growth and metastasis. Exercise augments T cell antitumor activity, and improved metabolic conditions help maintain sustained immune cell activation. Furthermore, exercise regulates the endocrine system, reducing the secretion of inflammatory factors, alleviating chronic inflammation, and lowering cancer risk. The regulation of estrogen levels by exercise also plays an important role in the prevention and treatment of hormone-dependent cancers, such as breast cancer. In summary, the available evidence suggests that exercise significantly inhibits cancer initiation and progression while improving treatment outcomes. Developing individualized exercise intervention plans for different cancer patients is expected to maximize clinical benefits. Future studies should further investigate the specific effects of various exercise types, intensities, and frequencies on different cancers to provide more precise exercise interventions. Particularly, exercise regimens should be personalized based on patients’ cancer type, disease course, and physical condition to ensure maximum clinical benefit. For example, assessing patients’ fitness levels and treatment stages can help tailor the most appropriate exercise types and intensities. Furthermore, the combination of exercise with chemotherapy, radiotherapy, and immunotherapy warrants further investigation to provide more effective comprehensive treatment strategies. Obesity and tumor metabolism Obesity is a chronic metabolic disorder characterized by excessive or abnormal fat accumulation, resulting from both genetic and environmental factors. The World Health Organization (WHO) defines overweight as a body mass index (BMI) between 25.0 and 29.9 kg/m² and obesity as a BMI of 30.0 kg/m² or above. With rising obesity rates in recent years, the impact of obesity on health has garnered increasing attention. Studies have shown that obesity is not only related to metabolic diseases such as type 2 diabetes and cardiovascular diseases but is also closely linked to the development and progression of various cancers, including breast, endometrial, gastric, colorectal, and renal cancers [455–461]. Obesity is a major factor contributing to poor prognosis in these cancers [462, 463]. Regular exercise and increased physical activity can lower cancer risk by preventing and managing obesity [464–466]. Obesity affects tumor initiation and progression through multiple mechanisms, including metabolic alterations, inflammatory responses, and immune regulation. Obesity influences the TME in various ways, including metabolic reprogramming of adipose tissue, which promotes cancer cell metabolic adaptation. Obesity is closely associated with dyslipidemia, which not only affects the energy supply to tumor cells but also promotes tumor initiation and progression by modulating lipid metabolism-related signaling pathways. For instance, under high-fat dietary conditions, cancer cells upregulate free fatty acid pathways and increase lipid uptake, suppressing CD8 + T cell infiltration and antitumor functions. Moreover, adipocytes within the tumor stroma provide free fatty acids as substrates for mitochondrial β-oxidation in tumor cells [467]. Obesity also leads to alterations in adipokine levels, such as leptin and adiponectin, which affect tumor metabolism and redox status. Adipose tissue, as an endocrine organ, secretes adipokines like adiponectin and leptin [468]. The imbalance between these adipokines due to obesity has a significant impact on cancer development and prognosis [469, 470]. Adiponectin, an anticancer factor, enhances insulin sensitivity and promotes apoptosis by activating ceramidase and reducing intracellular ceramide levels [471]. In contrast, leptin acts as a growth factor, stimulating cancer cell proliferation, such as in breast cancer, through activation of the PI3K and JAK/STAT signaling pathways [472, 473]. Obesity also triggers systemic chronic inflammation, which promotes cancer development. Obese patients have elevated levels of chronic inflammatory factors, such as interleukin-6 (IL-6) and TNF-α, which are associated with cancer initiation [474–478]. TNF-α promotes DNA damage and increases mutation burden [479], while IL-6 promotes tumor cell proliferation and invasiveness via excessive activation of STAT3 [480]. Furthermore, obesity is often accompanied by hyperinsulinemia, hyperglycemia, and insulin resistance, which affect cellular energy metabolism and promote cancer progression. Insulin resistance leads to compensatory hyperinsulinemia [481], which not only complicates glycemic control in type 2 diabetes patients but also promotes carcinogenesis through multiple pathways. High insulin levels activate IGF-1R and PI3K/AKT signaling pathways, enhancing cancer cell proliferation and survival. Insulin also promotes the secretion of inflammatory factors, further driving cancer progression. Cancer cells depend on glycolysis for energy [482], and elevated glucose levels provide an energy source for tumor cells [469], thereby promoting proliferation [483, 484]. Obesity also reshapes the TME by affecting immune cells, promoting tumor growth and metastasis. The TME in obese patients is predominantly infiltrated by immunosuppressive cells, such as M2-type tumor-associated macrophages and myeloid-derived suppressor cells, which release TGF-β to inhibit immune responses [485, 486]. Meanwhile, cytotoxic CD8 + T cells and NK cells are reduced in obese patients, leading to impaired immune surveillance and increased cancer risk [487, 488]. Lastly, obesity alters the composition of the gut microbiota and the properties of the intestinal epithelium, compromising barrier function and affecting tumor progression [489]. For example, high-fat and low-fiber diets can lead to reduced gut microbiota diversity, which is associated with cancer development [490]. In summary, obesity influences cancer initiation, progression, and prognosis through multiple mechanisms, including metabolic dysregulation, chronic inflammation, hyperinsulinemia, insulin resistance, altered immune microenvironment, and dysbiosis. Specifically, the metabolic disorders, chronic inflammation, hyperinsulinemia, and immune dysfunction caused by obesity collectively promote tumor growth and metastasis. Therefore, preventing and managing obesity is a critical strategy for controlling obesity-related cancers. Metabolic reprogramming in mediating drug resistance in metastatic breast cancer During cancer metastasis, tumor cells undergo metabolic reprogramming to adapt to the new microenvironment, supporting their rapid proliferation and survival. This reprogramming includes the upregulation of glycolytic pathways, known as the Warburg effe ct, and alterations in lipid metabolism that modify membrane structure and signaling molecules, thereby enhancing the cell’s invasiveness and metastatic potential [491]. Additionally, the pre-metastatic niche (PMN) itself undergoes significant metabolic changes, creating a conducive environment for tumor cell colonization and growth. Tumor-derived exosomes play a crucial role in this process by transporting microRNAs (miRNAs) that regulate glucose metabolism in target cells, thereby altering the local metabolic landscape. Moreover, stromal and immune cells within the PMN also experience metabolic reprogramming, characterized by lactate accumulation and increased glutamine metabolism. These changes not only provide energy and essential metabolic intermediates but also promote tumor growth and metastasis by modulating the function of these cells [492, 493]. Understanding the mechanisms underlying metabolic reprogramming in both tumor cells and the PMN is essential for the development of novel therapeutic strategies aimed at halting cancer metastasis and improving patient outcomes. During breast cancer metastasis, tumor cells frequently develop resistance to treatment, significantly complicating and challenging therapeutic efforts. This resistance can be either intrinsic, meaning it is present before treatment initiation, or acquired, where resistance emerges gradually following initial therapy [494]. MDR is a primary cause of treatment failure in breast cancer, with tumor cells employing a range of mechanisms to evade therapeutic effects. These mechanisms include the upregulation of drug efflux pumps (such as P-glycoprotein, breast cancer resistance protein, and MDR-associated protein 1), enhanced DNA repair capabilities, evasion of cellular senescence, epigenetic modifications, and phenotypic alterations via EMT [495]. These adaptations enable tumor cells to withstand chemotherapy and targeted therapies, often leading to recurrence and further metastasis [496]. Resistance is particularly pronounced in TNBC, which lacks hormone receptors and HER2 expression, rendering it unresponsive to conventional endocrine and HER2-targeted therapies, thus heavily reliant on chemotherapy. However, TNBC cells often develop resistance to chemotherapeutic agents, exacerbating the treatment challenges [494]. Similarly, approximately 50% of HER2-positive breast cancer patients treated with trastuzumab develop resistance, which significantly limits the long-term efficacy of the therapy. TME also plays a critical role in fostering drug resistance in breast cancer. Within the TME, stromal and immune cells engage in complex interactions with tumor cells, transmitting pro-tumor growth and drug resistance signals [497]. The miRNAs are key mediators in this intercellular communication, regulating interactions between stromal and tumor cells and promoting the development of drug resistance. To combat drug resistance in breast cancer, researchers are investigating a variety of innovative strategies, including nanomedicine delivery systems, combination therapies, and approaches targeting specific molecular pathways. These strategies aim to enhance drug selectivity and efficacy in tumor cells while minimizing the development of resistance, thereby improving therapeutic outcomes and patient survival. Impact of metabolic reprogramming in the PMN on drug resistance Cancer metastasis is a dynamic cascade process involving the mutual remodeling of cells and their microenvironment. For cancer cells to metastasize successfully, they must gain adaptive advantages through clonal selection, overcoming selective microenvironmental pressures at each dissemination, transport, and colonization stage [498]. They exhibit plasticity and evolutionary adaptability at several critical junctures to establish a PMN in the target organ, creating a microenvironment conducive to the colonization of metastatic tumor cells [499]. A PMN is formed when the primary tumor induces extracellular matrix remodeling, angiogenesis, lymphangiogenesis, and changes in the immune environment in distant organs through paracrine signaling and other mechanisms before metastatic spread occurs [500]. This series of changes disrupts tissue homeostasis, induces inflammatory responses, reduces immune surveillance, and increases vascular and lymphatic permeability, thereby facilitating tumor cell adhesion and growth [501, 502]. The concept of the PMN was first reported using lung and B16 melanoma tumor models. Primary tumors can induce ECs and macrophages in distant lung tissues to secrete MMP9 by releasing VEGF and PlGF, thereby remodeling the lung microenvironment to create conditions favorable for cancer cell infiltration and colonization, promoting lung metastasis [503, 504]. Another animal model study found that fibroblasts in organs distant from the primary tumor, which had not yet undergone metastasis, secrete a protein called fibronectin, a ligand for VLA-4. This attracts bone marrow-derived hematopoietic progenitor cells marked by VEGFR1 and VLA-4, mediating metabolic remodeling, enhancing tumor cell invasiveness, and inducing resistance to cancer therapies. VEGFR1-positive cell clusters are commonly observed in organs prone to tumor metastasis but not in healthy individuals [505, 506]. These pioneering studies elucidate how PMNs create a favorable microenvironment for tumor cells in distant organs at the molecular and cellular levels, thereby promoting tumor cell dissemination and colonization (Fig. 4). Molecular Mechanisms of Breast Cancer Metastasis, Drug Resistance, and Target Organ Selection.A Breast cancer cells acquire both intrinsic and adaptive drug resistance during metastasis through genetic mutations, clonal selection, and therapy-induced adaptations, complicating treatment strategies. B Tumor-Derived Factors. Direct Factors: VEGF, PlGF, TGF-β, MMP9, and exosomes promote angiogenesis, cell migration, and microenvironment remodeling, facilitating metastatic niche formation in target organs. Indirect Factors: MMP2, HIF-1α, CXCL1/CXCL12, and neutrophils enhance invasiveness and immune evasion, supporting metastasis across multiple organs. C Brain Metastasis: Breakdown of the blood-brain barrier, mediated by CXCL12, VEGF, and exosomes, promotes tumor cell colonization and angiogenesis in the brain. D Lung Metastasis: VEGF, MMP9, and LOX drive angiogenesis, extracellular matrix degradation, and cell adhesion, promoting tumor growth and dissemination in the lungs. E Bone Metastasis: Tumor cells trigger bone destruction via the RANKL-RANK signaling pathway and TGF-β release, creating a vicious cycle that accelerates bone metastasis. F Liver Metastasis: HIF-1α, VEGF, and CXCL12 foster fibrosis, immune modulation, and angiogenesis, facilitating tumor colonization and growth in the liver A study of over 700 metastatic tumor samples revealed crucial interactions between tumor cells and the microenvironments of specific distant organs [507]. These interactions not only promote the formation of s PMNs but also play a pivotal role in the metabolic reprogramming necessary for metastasis [508, 509]. PMNs are characterized by increased vascular permeability, extracellular matrix remodeling, local inflammation, formation of new blood and lymphatic vessels, changes in resident cells such as fibroblasts and epithelial cells, and the mobilization and immunosuppression of bone marrow-derived immune cells [510]. These features collectively facilitate the survival and proliferation of metastatic tumor cells. Moreover, the organ-specific tropism of PMNs allows them to target the microenvironments of organs selectively [511–513]. Metabolic reprogramming further equips them with the capability to obtain the necessary nutrients and energy in these new environments [514–516]. By creating an immunosuppressive and nutrient-rich local microenvironment, PMNs support the infiltration, colonization, and subsequent growth and spread of metastatic cancer cells [517–519]. In summary, the construction of PMNs is a multi-stage process that involves complex signaling exchanges between the primary tumor and potential metastatic target organs. This process mobilizes and activates different cell types, whose interactions within the microenvironment collectively drive tumor metastasis and resistance [520–522]. Primary tumor cells in metastatic breast cancer Primary tumor cells undergo extensive metabolic reprogramming to survive under limited nutrient and oxygen conditions, enabling them to adapt to new microenvironments during metastasis [523]. The formation of the PMN by primary tumors involves systemic changes, including the release of tumor-derived factors such as TGF-β, VEGF, and IL-6, as well as exosomes, EVs, and circulating free DNA (cfDNA) [524, 525]. These factors activate signaling pathways that reshape distant organ microenvironments, induce inflammation, and create metabolic conditions favorable for metastatic colonization. Tumor-derived soluble factors stimulate angiogenesis and suppress immune surveillance, while EVs and cfDNA play crucial roles in tumor progression and immune evasion [523]. Tumor-derived secreted factors (TDSFs) mobilize and recruit bone marrow-derived cells to the PMN, facilitating its establishment [526]. Hypoxia and inflammatory signals within the primary TME further drive the production of TDSFs, enhancing the activity of bone marrow-derived cells [527]. Cytokines such as G-CSF and IL-1 induce myeloid cells to adopt an immunosuppressive phenotype, which suppresses anti-tumor immune responses, promoting immune evasion and metastasis [528]. HIF-1 activation drives the migration of granulocytic MDSCs to the lungs, contributing to metastatic spread [527]. Pro-inflammatory cytokines like IL-1 and IL-18 play pivotal roles in metabolic reprogramming, tumor invasion, and angiogenesis, all of which contribute to metastasis and therapeutic resistance [529]. Interestingly, elevated IL-1β expression in primary tumors has been associated with improved survival and reduced metastasis in breast cancer patients, highlighting its complex role in cancer progression [526]. Breast cancer cell-derived cytokines significantly affect immune cells, such as macrophages and T cells, as well as stromal cells like fibroblasts, creating a supportive microenvironment at metastatic sites [530]. Th2 cytokines, including IL-4, activate STAT6, enhancing the recruitment of lung-resident mesenchymal stem cells (LMSCs) [531]. Furthermore, tumor cells secrete cytokines that recruit immunosuppressive macrophages and neutrophils, promoting tumor invasiveness and EMT through mechanisms such as ECM remodeling and TGF-β secretion [532, 533]. Therapeutic resistance in tumors is not solely driven by genetic mutations; it also involves non-genetic mechanisms. Drug-tolerant persister (DTP) cells exhibit characteristics such as slow proliferation, metabolic flexibility, and phenotypic plasticity [534]. A mesenchymal DTP state, regulated by the transcription factor ZEB1, relies on lipid peroxidation to prevent ferroptosis, thereby contributing to resistance [535]. Metastatic cells evade immune detection by entering a dormant state, allowing them to persist in distant organs [536]. Breast cancer metastases expressing stem cell markers like SOX2 and SOX9 exhibit slow proliferation through modulation of the Wnt signaling pathway, facilitating evasion of NK cell-mediated clearance [537]. Primary tumor cells also secrete growth factors, including VEGF, placental growth factor (PlGF), CD44v6, and CCL2, which recruit both immune and stromal cells to support metastasis [538, 539]. VEGF plays a crucial role in promoting angiogenesis and metabolic reprogramming, thereby enhancing metastatic cell survival [540]. PlGF, a member of the VEGF family, and CD44v6 contribute to tumor progression, invasion, and metastatic spread [539]. Chemokines such as CCL2 facilitate tumor cell infiltration by recruiting bone marrow-derived cells and guiding cancer cells to metastatic niches, altering the microenvironment to promote metastasis and therapeutic resistance [541]. Extracellular EVs are critical mediators of tumor-host communication and PMN formation. They modulate immune responses, alter vascular permeability, remodel the ECM, and deliver biomolecules—including RNA, DNA, and proteins—to recipient cells, thereby reprogramming the metastatic microenvironment. Exosomes, a subset of EVs, have been shown to promote lung metastasis by reshaping the immune landscape of distant organs. Specifically, they inhibit NK cell function, recruit immune cells, and activate stromal cells, facilitating the establishment of a supportive metastatic niche. Exosomal miR-21 promotes osteoclast differentiation, contributing to bone metastasis, while Lin28B-positive breast cancer cells use exosomes to induce immunosuppression in the pre-metastatic lung niche [542, 543]. Circulating tumor DNA (ctDNA), released by tumor cells into bodily fluids, forms cfDNA that offers critical insights into cancer progression [544]. Analysis of cfDNA can identify tumor-specific mutations, copy number variations, and epigenetic alterations, providing valuable information about the TME, immune status, and mechanisms of therapeutic resistance. Breast cancer-derived cfDNA has been shown to alter the microenvironment of distant metastatic organs, facilitating tumor cell colonization. Research indicates that cfDNA plays an essential role in PMN formation, thereby offering a potential target for new intervention strategies [545]. In summary, primary tumor cells drive metastasis and therapeutic resistance through the secretion of cytokines, EVs, and cfDNA, which collectively remodel the microenvironment of potential metastatic organs to support metastatic colonization. Cytokines such as TGF-β, VEGF, and IL-6 promote angiogenesis and immune suppression, while EVs mediate communication between tumor cells and distant tissues, and cfDNA modifies the microenvironment to enhance metastatic potential. These components are integral to PMN formation and collectively establish a supportive niche for metastatic cell survival and growth. Immunosuppressive cells Among the wide array of immunosuppressive cytokines, IL-10, TGF-β, IL-4, and IL-35 predominate in the TME across various cancers, playing a primary role in immune suppression. These tumor-derived growth factors, inflammatory cytokines, chemokines, and exosomes are key to initiating and evolving the PMN, playing effect to modulate immune cell activity and recruit immunosuppressive cells such as MDSCs, TAMs, and Tregs to accumulate in the PMN [546, 547]. By altering the immune status of the microenvironment, these cytokines affect the drug sensitivity of cancer cells, and contribute to the development of drug resistance [548, 549]. For example, MDSCs, secrete metabolic products like lactate, enriching the TME and playing a crucial role in tumor-associated immunosuppression [550, 551]. Neutrophils, for instance, have been shown to secrete leukotrienes that selectively induce cancer cell metastasis. Additionally, NETs, formed by activated neutrophils, can remodel the extracellular matrix and awaken dormant cancer cells, facilitating metastasis [552, 553]. MDSCs are critical in PMN formation due to their significant immunosuppressive capabilities. The presence of MDSCs in tumor tissues is closely linked to poor patient prognosis and therapeutic resistance [554]. High levels of MDSCs are considered potential predictive markers for adverse reactions to immune checkpoint inhibitors in various solid tumors. In the cancer inflammatory environment, various growth factors alter myeloid cell differentiation, creating highly immunosuppressive cell subtypes. Research indicates that increased mTOR signaling activation in cancer cells boosts G-CSF secretion, driving MDSC processes [555]. Tumor cell-secreted chemokines like CCL2, CXCL12, and CXCL5 recruit MDSCs to primary and metastatic sites [556]. However, MDSCs require additional signals to acquire immunosuppressive properties, typically mediated by STAT1, STAT3, STAT6, and NF-κB transcription factors [557, 558]. Tumor-secreted molecules like integrins recruit MDSCs to metastatic organs, where they synthesize S100A8/A9 proteins that activate the Src pathway [553, 559]. Additionally, S100A8/A9 proteins recruit neutrophils and PMN-MDSCs to pre-metastatic sites in CRC, forming a positive feedback loop [560]. Beyond their immunosuppressive effects, MDSCs also promote PMN formation [561, 562]. MDSCs inhibit effector T and NK cells, stimulate other inhibitory immune cells (Tregs, Bregs, TAMs), support cancer cell survival, aid immune evasion, promote angiogenesis, induce tissue remodeling, and enhance metastasis. Activated MDSCs can inhibit the functions of cytotoxic T cells and NK cells by producing ROS and Arg-1, thereby dismantling the body’s immune response. At metastatic sites, MDSCs can downregulate IFN-γ expression and secrete pro-inflammatory factors, creating an inflammatory microenvironment conducive to tumor growth. The PMN is characterized by clusters of myeloid cells expressing VEGFR1 and MMP-9 [563, 564]. MDSCs create a pro-metastatic microenvironment in lung cancer by secreting MMP-9 and TGF-β, promoting angiogenesis and metastatic spread [565, 566]. In metastatic breast cancer, MDSCs mediate immunosuppression, affecting cancer cell drug sensitivity through mechanisms involving PD-L1 expression and TGF-β secretion, which inhibit T cells and NK cells [567, 568]. MDSCs also impair T cell function by depleting L-arginine via ARG1 secretion [569]. Oxidative stress is another critical immunosuppressive mechanism of MDSCs. They produce iNOS and NOX2, generating NO and peroxynitrite, which inhibit T cell proliferation and migration [570, 571]. MDSCs also generate adenosine by expressing CD39 and CD73, further inhibiting T cell and NK cell functions. Cytokines like IL-10 and TGF-β not only suppress anti-tumor immunity but also promote Treg cell development, enhancing the immunosuppressive TME [572, 573]. Through immunosuppression, angiogenesis, extracellular matrix remodeling, and promotion of cancer cell stemness and EMT, MDSCs drive the progression and drug resistance of metastatic breast cancer. Understanding the mechanisms of MDSCs in these processes can aid in developing new therapeutic strategies to inhibit MDSC function and improve cancer treatment efficacy. TAMs are among the most abundant immune cell types in tumors. Research indicates that FAO and ROS can influence TAM recruitment, polarization, and phagocytic capacity, thereby affecting tumor metastasis. As tumors advance, TAMs shift from M0 and M1 phenotypes to M2 phenotypes, altering their metabolic mode from glycolysis to FAO and OXPHOS. Enhanced FAO efficiency increases TAM invasiveness within lipid-rich TME. The PPAR system, mediated by STAT6 and PGC-1β, promotes M2 polarization and FAO efficiency [574]. Proteins like S100A4 upregulate PPARγ and its downstream target CD36, facilitating fatty acid uptake and M2 polarization, while RIPK3-mediated Caspase-1 inhibits FAO. Additionally, ferroptosis through ROS oxidation damages FAO function, releasing exosomes containing KRASG12D. TAMs uptake KRASG12D via the RAGE receptor, promoting M2 polarization in a STAT3-dependent manner. These metabolic changes and TAM reprogramming are pivotal in the metastatic niche of breast cancer, influencing tumor resistance and progression [575]. IFN-TAMs, characterized by high expression of IFN-regulated genes such as CXCL10, PDL1, and ISG15, and M1-like markers like CD86 and MHCII, are present in cancers such as breast cancer (BRCA), CRC, and hepatocellular carcinoma (HCC). Among all TAM subpopulations, IFN-TAMs most closely resemble M1-like macrophages. However, contrary to the typical antitumor role of M1-like macrophages, IFN-TAMs exhibit immunosuppressive functions. They suppress immune responses through tryptophan degradation and recruitment of immunosuppressive Tregs. High expression of immune checkpoint molecules such as PD-L1 and IDO in IFN-TAMs is regulated by STAT1, STAT2, ETS variant transcription factor 7, and IFN regulatory factor 1 (IRF1) [576–578]. As a crucial component of the TME, TAMs significantly impact tumor growth, angiogenesis, immune regulation, metastasis, and chemotherapy resistance. Studies using flow cytometry, bulk RNA-seq, and protein expression analysis have identified FOLR2 + macrophages as perivascular tissue-resident macrophages associated with healthy breast tissue. Immunofluorescence detection revealed a positive correlation between the density of FOLR2 + macrophages and increased survival in breast cancer patients [579, 580]. Understanding the complex roles and metabolic reprogramming of TAMs offers promising insights for developing targeted cancer therapies. Patients with various cancers, including breast cancer, often exhibit an increased neutrophil-to-lymphocyte ratio, which is an independent predictor of mortality. Previous studies have identified tumor-infiltrating neutrophils (TINs) as the immune cell population most strongly associated with poor prognosis across 25 types of cancer, including breast cancer [581, 582]. Studies have revealed that Aconitate Decarboxylase 1 (Acod1) is the most upregulated metabolic enzyme in TINs. Further investigation showed that TINs resist ferroptosis and promote breast cancer metastasis through high expression of Acod1. Knockout of Acod1 reduces TIN survival and accumulation, thereby enhancing the efficacy of immune checkpoint blockade therapy in treating breast cancer metastasis [583, 584]. However, this enhancement diminishes when ferroptosis is inhibited. Additionally, tumor-derived Cathepsin C (CTSC) has been reported to promote breast cancer lung metastasis by regulating neutrophil infiltration and NET formation at early metastatic sites. This finding supports the potential for targeting CTSC in cancer therapy [585, 586]. Limited evidence suggests that lung-infiltrating neutrophils can suppress CD8 T cells and NK cells in the pre-metastatic stage. However, it remains unclear whether neutrophils’ immunosuppressive abilities are inherent or acquired after infiltrating the lung microenvironment. This study demonstrates that the immunomodulatory role of neutrophils is induced by tissue-resident stroma, and targeting tissue-specific stromal factors is an effective strategy for preventing metastasis and enhancing immunotherapy efficacy [587]. Studies have reported chronic inflammation can elevate pulmonary CCL2 levels, which migrate to peripheral blood and recruit tumor-promoting MHCIIhi neutrophils to the lung tissue. The high accumulation of MHCIIhi neutrophils further facilitates breast cancer metastasis to the lungs and tumor cell colonization [588, 589]. As we know, neutrophils and macrophages play dual roles in tumor development and progression. Hematopoietic progenitor cells in the bone marrow can differentiate into pro-tumor N2 neutrophils and M2 macrophages under the influence of tumor cells and microenvironmental molecules. N2 neutrophils, stimulated by tumor-secreted G-CSF, produce ROS and exhibit RB1 loss, which inhibits immune cell function and T cell activity [590, 591]. Additionally, under the influence of G-CSF or TGF-β, N2 neutrophils rapidly proliferate in peripheral tissues. Similarly, CSF1, IL-13, or CCL2 can induce progenitor cells to differentiate into M2 macrophages, which secrete anti-inflammatory factors such as IL-10 and Arg-1, promoting the establishment of a metastatic niche. Polarized N2 neutrophils and M2 macrophages create an immunosuppressive microenvironment. N2 neutrophils induce CD8 + T cell apoptosis in the presence of TNFα and NO. Meanwhile, M2 macrophages enhance tumor invasion through Rho-GTPase-regulated VEGF/CCL-18 signaling or by secreting miR-501-3p-enriched EVs that modify the microenvironment [586, 592]. For these cells to exert their effects in metastatic organs, they must migrate and localize to specific sites. Tumor exosomes containing snRNA activate TLR3 to recruit pulmonary neutrophils, while Pit1 increases CXCL12 expression to mediate macrophage recruitment, thereby facilitating breast cancer metastasis. Thus, neutrophils and macrophages undergo phenotypic and functional polarization under the regulation of tumor signaling molecules. They are recruited to metastatic sites where they participate in and coordinate the formation of the PMN through immunosuppression and matrix remodeling. As a state of dysfunction that occurs during chronic infections and cancer, T-cell exhaustion is characterized by the progressive loss of T cell function, ultimately leading to a failure in immune response. In chronic inflammatory sites where target cell elimination fails and T cell receptor (TCR) signals persist, T cells can become “exhausted.” This state is marked by the increased co-expression of inhibitory checkpoint receptors such as PD-1, CTLA-4, TIM-3, and LAG-3. However, recent studies suggest that exhausted T cells may still proliferate within human tumors, though the extent to which these cells retain their anti-tumor functions remains unclear. The authors categorized the tumor immune microenvironment of breast cancer into two types based on the enrichment of exhausted T cells. They then conducted a detailed study of the functional differences between T cells in exhausted and non-exhausted tumors, demonstrating that T cells in the exhausted immune environment retain proliferative capacity and exhibit tumor-responsive characteristics [593–595]. Metabolic dysfunction of exhausted CD8 + T cells in the TME, along with sustained high expression of inhibitory receptors (IRs), leads to effector function impairment, which is a critical mechanism of resistance to immunotherapy. Adverse metabolic conditions in the TME, such as glucose deprivation, lipid overload, and hypoxia, can result in CD8 + T cell functional defects. Thus, identifying adverse metabolic factors in the TME could be key to preventing or reversing CD8 + T cell exhaustion. Combined targeting of IRs on the surface of exhausted CD8 + T cells offer a potential therapeutic approach for reversing their functional state. As research into immunotherapy resistance mechanisms progresses, its application will extend to a broader range of malignancies [596, 597]. In metastatic breast cancer, intratumoral CD8 + T cells can be classified into exhausted (TEX) and tissue-resident memory (TRM) phenotypes. Infiltration of CD8 + TRM cells is closely associated with a favorable prognosis in TNBC patients. Dual immune checkpoint blockade (ICB) therapy can enhance the cytotoxic capacity of CD8 + TRM cells, with ICB-induced anti-tumor responses correlating with increased function, quantity, and quality of these cells. Locally, CD8 + TRM cells protect the reactivation of secondary breast tumors. Furthermore, the genetic characteristics of CD8 + TRM cells are significantly associated with improved prognosis in TNBC patients receiving ICB therapy. These findings indicate that metabolic reprogramming and functional enhancement of CD8 + TRM cells in the TME may be crucial pathways to overcoming resistance in metastatic breast cancer [598, 599]. In summary, immunosuppressive cells undergo metabolic changes induced by tumor cell-secreted factors and are recruited to the PMN. Once enriched in the PMN, they secrete metabolic products that remodel the microenvironment, supporting the survival and proliferation of tumor cells, thereby creating a vicious cycle that promotes PMN formation and metastatic progression. Host matrix cells and their derivatives In addition to hematopoietic lineage cells, local stromal and epithelial cells also contribute significantly to the formation of the PMN [600]. VEGFR1 + hematopoietic bone marrow progenitor cells expressing VLA-4 interact with fibronectin from resident fibroblasts to initiate PMN formation. Various stromal cells, including CAFs, vascular ECs, and adipocytes, are recruited to the PMN, where they secrete numerous factors influencing angiogenesis, proliferation, invasion, and metastasis. They remodel the extracellular matrix (ECM), creating a supportive environment for tumor growth, facilitating the formation of vascular and lymphatic networks providing pathways for tumor cell dissemination, and acting as protective shields for tumor cells, preventing immune cells and therapeutic agents from penetrating tumor tissues. The metastasis process involves intricate interactions among fibroblasts, immune cells, perivascular cells, and epithelial cells. These interactions are essential for the homing of BMDCs, the formation of fibrosis, and the development of the PMN. Lysyl oxidase (LOX) plays a critical role in the formation and degradation of the ECM by mediating the cross-linking of its components. Additionally, LOX induces extensive collagen cross-linking in the liver, establishing a fibrotic microenvironment that supports cell survival and proliferation. In breast cancer bone metastasis, LOX regulates the bone microenvironment by creating osteolytic lesions, which provide a favorable foundation for the colonization of CTCs [601, 602]. Furthermore, the growth of metastatic tumors is influenced by the hydroxylation of collagens I and III. In hypoxic metastatic sites, the stabilization of hypoxia-inducible factor 1-alpha (HIF1α) upregulates collagen prolyl 4-hydroxylase (P4HA). This, combined with increased pyruvate uptake in cancer cells, enhances collagen stability and promotes the helical twisting of collagen, thus facilitating the growth of metastatic breast cancer cells in the lungs. The fibrotic microenvironment also promotes metastatic growth. Hypoxia-inducible factors in PMNs prompt ECs to secrete pro-angiogenic factors such as PDGF, epidermal growth factor (EGF), and VEGF [603, 604]. VEGF stimulates EC migration through both autocrine and paracrine mechanisms, leading to the formation of new vascular lumens. ECs then secrete proteins to form new basement membranes. However, the vasculature in PMNs often remains immature, resulting in a leaky vascular system. ECs are crucial in cancer cell migration, invasion, and metastasis due to their plasticity, allowing them to alter cell fate. In establishing the PMN at the target organ site, recruited foreign cells such as MDSCs, TANs, and macrophages create an immunosuppressive, pro-angiogenic, and pro-tumor cell adhesion microenvironment. This environment paves the way for tumor cell invasion. However, the key to the successful colonization and formation of metastatic tumors lies in the alterations of resident and stromal cells at the target organ site. Resident cells are fundamental to organotropism in metastasis. Hoshino et al. demonstrated that resident cells in different organ tissues can recognize and uptake exosomes bearing distinct integrins [500, 605, 606]. For instance, S100A4-expressing fibroblasts and surfactant protein C (SPC)-expressing epithelial cells in the lungs can uptake lung-targeting exosomes. Similarly, Kupffer cells in the liver uptake liver-targeting exosomes, and ECs expressing platelet-EC adhesion molecule 1 (PECAM-1/CD31) in the brain uptake brain-targeting exosomes. Normal cells at the target organ site can be transformed by tumor-secreted molecules into promoters of tumor progression. Costa-Silva et al. found that Kupffer cells in the liver can uptake exosomes from pancreatic ductal adenocarcinoma, inducing hepatic stellate cells to secrete more TGF-β and fibronectin. This secretion leads to fibrosis and the recruitment of macrophages, thereby establishing a PMN [607, 608]. Additionally, Sharma et al. discovered that alveolar macrophages receive proliferative signals through the complement C5a receptor (C5aR), inhibiting Th1 immune responses in the lung and promoting PMN formation. Moreover, Umakoshi et al. demonstrated that peritoneal mesothelial cells (PMCs), fibroblasts, and ECs in the stomach, upon contact with EVs secreted by macrophages, uptake RNA and protein components from these EVs. This uptake upregulates metastasis-related proteins such as Src, Wnt3, and hypoxia-inducible factor 1 (HIF1), transforming stromal fibroblasts into tumor-associated fibroblasts and inducing EMT in PMCs, thereby promoting the establishment of the PMN. In conclusion, resident and stromal cells at the target organ site, upon receiving metastatic signal molecules, alter their properties or interact with other cells, creating favorable conditions for the successful colonization and rapid growth of metastatic tumor cells [609, 610]. Breast cancer cells interact with local stromal cells in distant organs, inducing metabolic reprogramming that creates a favorable microenvironment for tumor colonization and spread, known as the PMN. Studies have shown that primary tumors can cause an accumulation of palmitate esters in the stromal fluid of distant organs, particularly in the lungs, reshaping the PMN. Metastatic breast cancer cells use these enriched palmitate esters for metabolic reprogramming via the CPT1a-acetyl-CoA-KAT2a-NF-κB p65 pathway, activating pro-metastatic transcriptional programs. This process not only promotes cancer cell colonization and growth but also increases their resistance to chemotherapy and other treatments [611, 612]. The metabolic reprogramming within the PMN provides nutritional support to cancer cells and confers drug resistance. In bone metastasis, for example, stromal cells in the bone microenvironment, such as osteoblasts, can induce endocrine therapy resistance in ER-positive breast cancer cells through various mechanisms. Osteoblasts may downregulate ER expression directly or indirectly and alter multiple metabolic pathways, with EZH2-mediated epigenetic reprogramming playing a key role. This reprogramming enhances endocrine resistance, increases the invasive capabilities of tumor cells, and promotes their spread from bone to other organs [613, 614]. Similarly, when breast cancer cells metastasize to the liver, lungs, brain, and other sites, local stromal cells such as fibroblasts and ECs undergo metabolic reprogramming. This reprogramming alters several aspects of the local microenvironment, including angiogenesis, inflammation, and ECM composition, supporting tumor cell survival and proliferation and influencing treatment sensitivity [615, 616]. In conclusion, changes in host stromal cells and their metabolic products during PMN formation significantly impact the treatment resistance of metastatic breast cancer. Further research into this process can elucidate the molecular mechanisms of breast cancer resistance and provide insights for developing new therapeutic strategies. Metabolic reprogramming in CTCs and its impact on drug resistance The “seed and soil” theory, first proposed by Stephen Paget in 1889, provides a foundational explanation for the selective colonization of tumor cells within specific organ microenvironments during metastasis. This theory analogizes the metastatic process to the germination of seeds (tumor cells) in a compatible soil (host tissue microenvironment), highlighting the critical roles of CTCs and the TME in metastatic progression [617]. CTCs, which are shed from the primary or metastatic tumor sites into the blood or lymphatic system, possess the ability to survive within the circulatory system and migrate to distant body sites, where they can eventually establish secondary tumors. Research has demonstrated that before the primary tumor releases TDSFs and EVs into the circulation, these factors act on bone marrow-derived DCs or tissue-resident histiocytes to modulate the microenvironment of the target organ, thereby creating a PMN that is conducive to the survival and colonization of CTCs [618]. This mechanism underscores the complexity of tumor metastasis and the pivotal role of the microenvironment in facilitating the successful establishment of metastatic tumors. CTCs are disseminated through the bloodstream and demonstrate remarkable biological plasticity, enabling them to reprogram their metabolism within the highly dynamic environment of the circulatory system. This adaptability is crucial for their survival and metastatic potential, as CTCs activate key energy signaling pathways such as PI3K/AKT [619] and RAS/MEK/ERK [620], facilitating their persistence and colonization in new ecological niches. Recent studies have utilized CTCs in the bloodstream as biomarkers, employing metabolic markers such as phosphoglycerate kinase 1 (PGK1) and glucose-6-phosphate dehydrogenase (G6PD) to classify these cells. These markers have proven effective in distinguishing CTCs with high metabolic activity, which has been strongly correlated with the prognosis of breast cancer patients. Specifically, elevated expression of PGK1 and G6PD in CTCs has been associated with shorter overall survival and recurrence-free survival [621, 622], thereby identifying potential therapeutic targets for combating metastatic breast cancer. Metabolic reprogramming is a hallmark of tumor cells, particularly during metastasis (Fig. 5). To survive within the circulatory system, CTCs must rapidly adapt their metabolic pathways to withstand harsh conditions. For instance, CTCs enhance serine synthesis by upregulating serine synthase (PHGDH) expression, which supports protein and nucleotide synthesis, one-carbon metabolism, and ultimately promotes cell proliferation [618]. Concurrently, lactate generated by CTCs through heightened glycolytic activity is exported from the cell via MCTs. This lactate not only serves as a substrate for surrounding fibroblasts but also promotes tumor cell invasion and metastasis by acidifying the local microenvironment. This comprehensive understanding of the metabolic adaptations in CTCs underscores their critical role in breast cancer progression and highlights potential avenues for therapeutic intervention targeting the metabolic vulnerabilities of these cells during metastasis [617]. Metabolic Pathways Driving Breast Cancer Metastasis and Drug Resistance.The upper left panel outlines the metastatic process of circulating tumor cells, emphasizing the role of the TME and the involvement of blood and lymphatic vessels in promoting cancer cell spread. The upper right panel highlights mechanisms that confer drug resistance to circulating tumor cells. The lower panel details the metabolic reprogramming in breast cancer cells, focusing on key pathways such as glucose uptake via GLUT transporters and its conversion to lactate through glycolysis. Glutamine metabolism, facilitated by the ASCT2 transporter, is depicted alongside related processes like one-carbon metabolism, lipid synthesis, nucleotide biosynthesis, and iron metabolism. The regulatory role of mTORC1 is highlighted in these pathways, as well as the link between ferroptosis and iron metabolism, involving molecules like transferrin, ferritin, and TFR1. Essential mitochondrial functions, including the TCA cycle and fatty acid oxidation, are also shown, which support cancer cell survival and proliferation under stress, including resistance to therapies. This figure encapsulates the metabolic adaptations that enable tumor cells to metastasize and resist treatment The metastasis of tumor cells within the cardiovascular and lymphatic systems plays distinct yet complementary roles in cancer progression. CTCs in the cardiovascular system are capable of rapidly reaching distant organs due to the swift circulation of blood, facilitating the formation of metastases in these sites [623, 624]. In contrast, tumor cells disseminating through the lymphatic system typically first establish metastases in regional lymph nodes, a process characterized by the low-pressure, slow flow of lymphatic fluid, before gradually spreading to other parts of the body [625, 626]. The rapid dissemination of CTCs via the bloodstream underscores their significance as a prognostic marker in cancer. Blood-based assays enable real-time monitoring of the quantity and characteristics of CTCs, providing valuable insights into tumor progression and the effectiveness of therapeutic interventions [627]. The detection and analysis of CTCs in the cardiovascular system have been validated in multiple clinical studies, reinforcing their critical role in cancer management [624]. Meanwhile, lymphatic vessels not only serve as a conduit for the spread of tumor cells but also play a crucial role in modulating the tumor immune microenvironment. Understanding the distinct mechanisms of tumor cell dissemination through these two systems is essential for improving cancer diagnosis, prognosis, and treatment strategies. This knowledge can guide the development of more precise therapeutic approaches tailored to the specific pathways of metastasis, ultimately enhancing patient outcomes. CTCs in the cardiovascular system Within the cardiovascular and lymphatic systems, CTCs serve as critical mediators of cancer metastasis, exhibiting unique phenotypic characteristics that enable them to survive, disseminate, and establish metastatic foci in distant organs [628, 629]. In the cardiovascular system, CTCs must adapt to the challenges posed by high shear forces and immune surveillance. Key phenotypes, such as EMT and epithelial-mesenchymal plasticity (EMP), confer increased resilience, playing a pivotal role in the metastatic process. EMT involves the transformation of epithelial cells into mesenchymal-like cells, characterized by the loss of cell polarity and intercellular adhesion. This transformation enhances the migratory and invasive capacities of CTCs, facilitating their entry into and survival within the circulatory system. EMT is associated with the activation of multiple survival pathways, including Akt, PI3K, and EGFR signaling, which inhibit apoptosis and anoikis, thereby promoting CTCs survival. Additionally, CTCs exhibit EMP in circulation, allowing them to dynamically switch between epithelial and mesenchymal states. This plasticity enables CTCs to better withstand the high shear forces and other unfavorable conditions in the bloodstream, thereby enhancing their survival and proliferation. Studies have shown that shear stress can induce changes in the nuclear volume of CTCs, affecting their viability and gene expression [630, 631]. The EMT process in various cancers is driven by a diverse set of transcription factors, such as SNAIL, TWIST, and ZEB, which often exhibit compensatory roles, making it difficult to completely inhibit EMT through a single therapeutic strategy. For instance, while TWIST1 expression is critical for the metastatic potential of breast cancer cells, other cancers may rely more on ZEB1 or SNAIL [632]. This redundancy in EMT pathways contributes to increased resistance to therapy and enhanced metastatic potential [633]. In the cardiovascular system, CTCs frequently form heterogeneous complexes with platelets, immune cells, and CAFs. These complexes enhance the stemness and proliferative capacity of CTCs by upregulating inhibitory checkpoint molecules and modulating the extracellular matrix environment, enabling CTCs to better adapt to circulatory stresses and evade immune surveillance [628]. The interaction between CTCs and platelets plays a key role in immune evasion and metastasis. Platelets not only physically shield CTCs from shear forces but also facilitate immune evasion by upregulating the inhibitory checkpoint molecule CD155 via the FAK/JNK/c-Jun signaling pathway, thereby promoting CTCs survival and proliferation. Furthermore, CAFs interact with CTCs within the TME, regulating the stem cell properties and proliferative capacity of CTCs through the secretion of growth factors and cytokines. For instance, CAFs can activate the Wnt signaling pathway through paracrine signals, such as hepatocyte growth factor (HGF), inducing the transformation of non-stem cells into circulating tumor stem cells (CCSCs) [634, 635]. CCSCs, a subpopulation of CTCs with stem cell markers, possess the potential for self-renewal and multidirectional differentiation and are closely associated with high metastatic risk, advanced malignancy staging, and drug resistance [636]. CCSCs maintain their stemness through several key molecular signaling pathways, including Wnt/β-catenin, Notch, and Hedgehog, which are critical for both normal stem cells and CCSCs [637, 638]. These pathways not only support the self-renewal and proliferation of CCSCs but also enable them to survive the hostile TME and resist conventional anticancer therapies [636]. A defining feature of CCSCs is their interaction with the TME, where stromal cells, vascular cells, and immune cells support CCSC maintenance and proliferation through the secretion of cytokines and growth factors. For example, the stiffness of the tumor stroma can activate the integrin-focal adhesion kinase (FAK) signaling pathway, further promoting CCSC survival and migration [637]. Additionally, CCSCs can protect themselves from immune system attacks by establishing a specific “niche” environment composed of tumor stromal and immunomodulatory cells, which inhibit immune cell function and enhance immune evasion. CTCs aggregates have also been linked to specific changes in DNA methylation that promote stemness and metastasis. It has been shown that the DNA of transcription factors associated with stemness and proliferation in CTCs aggregates, such as OCT4, NANOG, and SOX2, is often hypomethylated, leading to increased expression of these factors and enhancing the stemness and metastatic potential of CTCs. The co-expression of EMT and stem cell markers is critical for the successful establishment of distant metastases. EMT enables tumor cells to acquire mesenchymal characteristics, enhancing their migratory and invasive capabilities, while simultaneously promoting the acquisition of stem cell properties. This phenomenon has been validated in several cancer types, particularly in oral and breast cancers, underscoring the complexity of metastasis and the challenge of effectively targeting these processes in clinical settings [639, 640]. CTCs demonstrate remarkable metabolic plasticity and adaptability, essential traits for their survival and metastatic potential in dynamic microenvironments. Metabolic plasticity refers to the capacity of tumor cells to fulfill diverse metabolic demands through reprogramming, thereby supporting their metastatic journey. For instance, under hypoxic conditions, CTCs upregulate glycolytic pathways to meet their energy needs, while in well-oxygenated environments, they may shift towards OXPHOS to maintain energy homeostasis [641]. In this context, CTCs employ four key metabolic adaptation strategies: enhanced glycolysis, lipid metabolism, amino acid metabolism, and iron metabolism. These adaptive mechanisms enable CTCs to thrive in varying microenvironments, underscoring their role in facilitating metastasis. Glycolytic reprogramming is a crucial factor in the survival and colonization of CTCs. In breast cancer, elevated levels of pyruvate contribute to the production of α-ketoglutarate, which in turn activates collagen P4HA, facilitating collagen hydroxylation. This process is critical in forming PMN, thereby promoting the colonization and growth of breast cancer-derived lung metastases [642]. Moreover, PHGDH interacts with the glycolytic enzyme phosphofructokinase (PFK). When PHGDH expression is low, it activates the hexosamine-sialic acid pathway, leading to aberrant protein glycosylation, including increased sialylation of integrins αvβ3 [643]. This modification enhances the migratory and invasive capabilities of cancer cells. Collectively, these findings underscore the pivotal role of glycolytic flux in the metastatic cascade, revealing potential vulnerabilities in the transition of cancer cells to CTCs and the formation of secondary tumors. The distant metastasis of CTCs is critically dependent on the PPP [644], which comprises both oxidative and non-oxidative branches, each producing essential metabolites for cancer cell metabolism. The oxidative branch of the PPP (oxPPP) is catalyzed by G6PD to generate NADPH, which is vital for maintaining intracellular redox homeostasis [645]. Meanwhile, the non-oxidative branch produces ribose-5-phosphate, a key precursor for nucleotide biosynthesis. Both products are indispensable for the survival and proliferation of CTCs. In breast cancer, the overexpression of Rac1 has been shown to regulate glycolysis and the PPP, enhancing nucleotide metabolism and promoting the repair of chemotherapy-induced DNA damage [339]. Additionally, another study identified transaldolase 1 (TALDO1) as a rate-limiting enzyme in the PPP, which may promote breast cancer metastasis through its positive regulation of redox and energy metabolism. Both in vivo mouse models and patient-derived organoid (PDO) models have demonstrated that the TALDO1 inhibitor AO-022 effectively inhibits breast cancer progression. These findings suggest that metabolic reprogramming of the PPP could serve as a biomarker for cancer detection and a promising target for the development of novel anticancer therapies. The role of PPP in supporting CTCs underscores its potential as a therapeutic vulnerability in the management of metastatic cancer. The enhanced expression of GLUT proteins and metabolic enzymes is intimately linked to rapid tumor proliferation and the maintenance of stem cell properties [646]. Emerging evidence indicates that the selective regulation of key enzymes in glycolysis and the PPP, a pathway parallel to glycolysis, results in distinct tumor phenotypes [647, 648]. In gastric cancer, heat shock protein 90 (HSP90) has been shown to form multiple enzyme complexes that increase the efficiency of glycolysis. HSP90 also interacts with cytoskeleton-associated proteins, such as MYH9 and ACTIN, to regulate the spatial distribution of glycolytic enzymes within tumor cells. This precise localization through cytoskeletal dynamics ensures an optimized energy supply, thereby promoting processes like EMT, which in turn enhances malignant phenotypes such as migratory invasiveness and stemness [649]. PHGDH, the rate-limiting enzyme in serine biosynthesis, plays a crucial role in this context. Deficiency in PHGDH has been shown to promote metastatic seeding in TNBC by facilitating EMT, suggesting that glycolytic flux is essential for the survival of cells undergoing this transition [643]. Therefore, targeting glycolytic pathways may expose a metabolic vulnerability in cells experiencing EMT, offering potential therapeutic strategies for combating tumor metastasis and progression. Fatty acid metabolism plays a pivotal role in the EMT and metastatic cascade of cancer cells by mitigating oxidative stress, promoting tumor invasion and metastasis, and contributing to resistance against targeted therapies [650]. In breast cancer, enhanced FAO activity is crucial for maintaining acetylation of histone H3 at lysine 27 on the promoters of EMT-related genes, thereby sustaining the EMT phenotype [651]. The deletion of OVOL2 has been shown to promote FAO through the activation of STAT3 signaling, which increases the production of ATP and NADPH. These molecules support the stem cell-like features of TNBC cells by boosting cellular energy production and antioxidant capacity. As a result, OVOL2 has been identified as a potential therapeutic target for modulating FAO and tumor cell stemness [652]. Moreover, the JAK/STAT3 signaling pathway plays a critical role in the self-renewal of breast cancer stem cells (BCSCs) by upregulating the expression of multiple lipid metabolism genes, including CPT1B, a key enzyme involved in FAO [85]. This pathway’s activation underscores the importance of lipid metabolism in maintaining the stemness and metastatic potential of BCSCs, suggesting that targeting these metabolic processes could provide new avenues for therapeutic intervention in breast cancer. Elevated levels of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α), a key regulator of mitochondrial biogenesis, along with the upregulation of genes involved in OXPHOS, have been observed in CTCs from breast cancer patients and mouse models compared to primary tumors. This suggests a significant role for increased mitochondrial activity in facilitating metastasis [653]. In TNBC, a decrease in CD24 expression has been associated with a heightened reliance on the mitochondrial FAO pathway, leading to enhanced cell proliferation, colony-forming capacity, and stem cell-like properties that drive tumor progression and metastasis [654]. Mitochondria are central to these processes, underscoring their importance in cancer biology. In other cancers, mitochondrial fission has been shown to regulate fatty acid metabolic reprogramming by inhibiting SIRT1 activity, upregulating SREBP1, and downregulating PGC-1α/PPARα. These alterations promote the proliferation, metastasis, and in vivo tumor growth of hepatocellular carcinoma cells [655]. This body of literature highlights the stage- and environment-dependent changes in mitochondrial and fatty acid metabolism, indicating a need for further investigation into these dynamic metabolic alterations and their implications for cancer progression and treatment. Defective glycolysis in breast cancer cells can lead to a shift toward fatty acid-dependent OXPHOS for energy production [656]. Akr1b8 and its human homolog AKR1B10, members of the aldo-keto reductase (AKR) superfamily, are central to this metabolic shift. Unlike the well-known Warburg effect, high expression of AKR1B10 in breast cancer reduces reliance on glycolysis and enhances FAO, a metabolic change that, while not affecting primary tumor growth or the onset of metastasis, promotes the expansion of metastatic foci [657]. Additionally, studies have shown that cisplatin-resistant cells increase fatty acid (FA) uptake while decreasing glucose uptake and lipogenesis, indicating a metabolic reprogramming from glucose to fatty acid-dependent anabolism and energy metabolism [658]. Amino acid metabolic reprogramming is a key feature of adaptive changes in breast cancer, particularly in TNBC. Non-coding RNAs, including lncRNAs, interact with mRNAs of metabolism-related genes and are crucial in regulating amino acid metabolic reprogramming in breast cancer [659, 660]. Recent research has primarily focused on pathways involving glutamine and serine metabolism. Glutamine plays a multifaceted role in cellular metabolism, including regulating antioxidant levels, providing biosynthetic precursors [661], and driving the TCA cycle to maintain mitochondrial function through anaplerotic processes in various cancers [93]. In breast cancer, the expression of the glutamine transporter ASCT2 correlates with tumor type and progression [94, 662]. Glutamine hydrolysis further regulates cancer cell proliferation [663]. Enzymes involved in glutamine metabolism, such as GLS 1/2 [664], glutamine synthetase [665], glutamate dehydrogenase (GDH) [666], and transaminases [667], alongside transporters like SLC1A5 [668], SLC38A2 [669], and SLC38A3, play critical roles in modulating the tumor cell environment and metastasis. Cancer cells also utilize glutamine and cystine metabolism to alter cell adhesion and activate invasive signaling pathways [670]. Moreover, GDH, which converts glutamate to α-ketoglutarate, has been identified as a prognostic marker for CRC metastasis [671]. Inhibition of GDH, either through knockdown or R162, reduces resistance to anoikis and decreases tumor metastasis via the CamKK2-AMPK signaling pathway in LKB1-deficient lung cancer models. This highlights the importance of glutamine metabolism in cancer progression and metastasis [672]. Serine metabolism is closely linked to tumor metastasis and redox homeostasis [673]. PHGDH, a key enzyme in serine biosynthesis, plays a crucial role in serine starvation tolerance, ROS regulation, and resistance to therapies such as sorafenib. In breast cancer, low PHGDH expression in CTCs and early metastatic stages enhances metastasis by promoting EMT and invasion [643]. However, high PHGDH expression may aid in the colonization of serine-deficient environments, such as the brain, by facilitating serine synthesis [674]. Serine is known to stimulate proliferation in various cell types, and in bone-metastatic breast cancer, L-serine promotes both osteoclastogenesis and tumor cell proliferation, underscoring the importance of the serine biosynthetic pathway. Serine deprivation can also cause mitochondrial dysfunction in tumor cells, leading to cytoplasmic accumulation of mitochondrial DNA and subsequent activation of the cGAS-STING signaling pathway, which limits tumor growth [675]. Additionally, serine/glycine metabolism and redox homeostasis in CRC may be regulated by CircMYH9 through p53 overexpression, promoting tumor proliferation [676]. Under hypoxic conditions, serine catabolism supports mitochondrial redox control, which is vital for cancer cell survival in low-oxygen environments [677]. Iron is a crucial element for various metabolic functions, including respiration, oxygen transport, anabolic processes, and redox reactions. Aberrant regulation of iron metabolism-related genes has been shown to promote tumor cell proliferation, invasion, and metastasis. Masui et al. demonstrated that mTORC2 regulates iron metabolism in glioma cells by modulating histone H3 acetylation in the promoter regions of iron-related genes, thereby maintaining the malignant characteristics of these cells [678]. Tumor cells can increase intracellular iron levels by regulating the expression of transferrin receptors, iron transporter proteins, and ferritin to manage their iron dependency. Elevated ferritin expression in CTCs is associated with poor prognosis in breast cancer patients [679]. Additionally, CYB561 has been shown to regulate iron metabolism through the activation of the Akt/mTOR signaling pathway, enhancing the proliferation, migration, and invasiveness of breast cancer cells. Furthermore, microarray analyses of breast cancer clinical samples have linked the Hippo signaling pathway to iron metabolism, with significant associations observed with poor patient outcomes [680]. During EMT, cancer cells can acquire iron through a CD44-hyaluronic acid complex, an alternative to conventional iron uptake pathways like transferrin receptor 1, which often fail to meet the heightened iron demands of malignant cells. Various cytokines and growth factors induce the upregulation of CD44, a surface molecule that facilitates the internalization of iron bound to hyaluronic acid. This CD44-mediated endocytosis becomes the primary mechanism for iron acquisition in cancer cells undergoing EMT [681], supporting their transition to a more aggressive mesenchymal state. The increased iron supply is crucial for the expression of mesenchymal genes, including those encoding TGF-ß, which is essential for EMT and cancer progression [681]. CTCs in the lymphatic vascular system Lymphatic CTCs (LCTCs) are tumor cells that enter the lymphatic system from the primary tumor and migrate toward sentinel lymph nodes during metastasis. While LCTCs share similarities with blood CTCs (BCTCs), they exhibit distinct gene and protein expression profiles. Notably, LCTCs often exist as cell clusters, a formation that may enhance their survival and metastatic potential within the lymphatic system. In the lymphatic fluid, LCTCs display both epithelial (adhesion) and mesenchymal (migration) properties, leveraging EMP and cancer stem cell-like characteristics to adapt to varying environments [682]. LCTCs also gain a survival and colonization advantage through immune evasion mechanisms. They evade immune clearance by altering antigen processing and presentation pathways, thereby reducing recognition by the immune system. Tregs, MDSCs, and polarized macrophages further support this evasion by secreting immunosuppressive cytokines. In the lymphovascular system, LCTCs promote lymphangiogenesis and facilitate metastasis to lymph nodes by upregulating lymphangiogenic factors such as VEGF-C and VEGF-D [683]. Interactions between lymphatic vessel ECs and LCTCs create favorable conditions for colonization, while also releasing immunosuppressive signals that impair immune surveillance. Additionally, LCTCs express higher levels of genes related to cell cycle control, DNA damage repair, and apoptosis compared to primary tumors and BCTCs, aiding their survival during migration to the lymph nodes [684]. LCTCs adjust their fatty acid metabolism to enhance survival and metastasis within the lymphatic system. Enhanced FAO supports the unanchored survival of LCTCs in tumor-draining lymph nodes [685]. Additionally, patients with lymph node metastases exhibit reduced plasma glutamine levels and significantly higher glutamate concentrations compared to those without metastases, suggesting metabolic reprogramming linked to lymphatic metastasis [670, 686]. LCTCs experience lower levels of ROS-induced ferroptosis than cells undergoing hematogenous metastasis. This resistance is partly due to the high uptake of oleic acid from vesicles in lymphatic fluid, which results in unsaturated cell membranes and reduced sensitivity to lipid peroxidation, allowing LCTCs to better withstand ROS toxicity [687]. This highlights the critical role of the metabolic environment in promoting metastasis. In contrast, ferritin-related resistance mechanisms are more prominent in cells metastasizing through the bloodstream [687]. In the breast cancer lymphatic system, LCTCs can reprogram their metabolism through autophagy to adapt to the extreme microenvironment, thereby supporting their survival and facilitating further metastasis. Autophagy allows LCTCs to cope with nutrient and oxygen shortages in lymphatic vessels by breaking down unnecessary or damaged cellular components, thus sustaining energy metabolism and enhancing survival [688]. Moreover, autophagy influences the activation of downstream signaling pathways, such as the BNIP3/NIX pathway, which supports CTCs survival and proliferation under stress conditions [689, 690]. Finally, autophagy-regulated LCTCs can interact more effectively with cellular metabolism and the TME, promoting tumor cell proliferation and invasion [691] . Metabolic reprogramming of CTCs plays a pivotal role in the development of drug resistance. Targeting these metabolic alterations may offer a promising strategy to reverse or delay chemoresistance, with metabolic inhibitors used in combination with chemotherapeutic agents showing potential as an effective treatment approach. Increasing evidence indicates that aerobic glycolysis not only promotes tumor cell proliferation but is also closely associated with chemoresistance. Thus, targeting glycolysis may enhance the efficacy of chemotherapy. In breast cancer, significant activation of the AKT signaling and glycolysis pathways has been observed in lapatinib-resistant cell lines, and inhibiting glycolysis effectively increased the sensitivity of these resistant cells to lapatinib [692]. Similarly, in clinical samples of drug-resistant gastric cancer, upregulation of the glycolytic pathway led to increased lactic acid production and enhanced DNA damage repair, contributing to drug resistance [693]. Lipids also play a critical role in cancer metastasis and drug resistance. In HER2-positive breast cancer, CD36-mediated fatty acid uptake becomes the primary source of lipids during the development of resistance to targeted therapy, surpassing fatty acid synthesis [694]. Lipid metabolism has also been implicated in sunitinib resistance in renal cell carcinoma [695]. Additionally, in vitro and mouse model studies suggest that a low-protein diet can block the nutrient-regulated mTORC1 signaling pathway, thereby inhibiting uncontrolled cancer cell growth and reversing drug resistance [696]. In summary, metabolic reprogramming in tumor cells is a key driver of chemotherapy resistance. Combining metabolic pathway inhibitors with traditional chemotherapeutic agents could significantly enhance tumor cell sensitivity to treatment, offering new prospects for overcoming drug resistance in cancer therapy. Conclusion and future directions This review systematically examines the role of metabolic reprogramming in the development of therapeutic resistance in both primary and metastatic breast cancer. In primary tumors, cancer cells undergo significant shifts in metabolic pathways, such as enhanced glycolysis (Warburg effect), lipid synthesis, and amino acid metabolism, to support their rapid proliferation and survival under stress. These metabolic adaptations not only drive tumor progression but also contribute directly to chemotherapy resistance, making it difficult to achieve effective treatment outcomes. Similarly, the metastatic sites exhibit unique metabolic profiles, often distinct from the primary tumor, which further complicates therapy. Metabolic plasticity in metastatic lesions allows cancer cells to thrive in diverse organ environments and evade the effects of targeted therapies and immunotherapies. The interaction between tumor cells and TME-immune cells plays a very important role in modulating metabolic resistance. Moreover, immune cell metabolism, such as TAMs and T cells, is shifted, further reinforcing the ability of the tumor to become resistant to treatments. Such a dual analysis of primary versus metastatic disease in breast cancer highlights the need to address metabolic vulnerabilities at various stages of disease progression. It is brightly promising that therapeutic strategies aimed at inhibiting key metabolic pathways, such as glucose and lipid metabolism, hold a great future in overcoming drug resistance. Targeting metabolic reprogramming in the TME, especially immune components, could be another way to improve the efficacy of existing treatments further. Personalized therapies exploiting distinct metabolic adaptations in metastatic niches may offer a possible future breakthrough in treating metastatic breast cancer. Understanding these metabolic changes is paramount in devising better therapies that might be able to outsmart resistance to improve outcomes not only in early-stage but also in advanced breast cancers. Supplementary Information Supplementary Material 1. Acknowledgements This work is funded by the Harbin Medical University Youth Fund (Grant No. 2023-KYYWF-0202). All the figures were created with Biorender.com. Abbreviations Hormone Receptors Human Epidermal Growth Factor Receptor 2 Triple-Negative Breast Cancer Tumor Microenvironment Oxidative Phosphorylation Fatty Acid Oxidation Glucose Transporters Monocarboxylate Transporters Hexokinase Phosphofructokinase-1 Pyruvate Kinase Lactic Acid Dehydrogenase Nicotinamide Adenine Dinucleotide Phosphate Pentose Phosphate Pathway Fatty Acid Synthase Tricarboxylic Acid Glutaminase Mammalian Target of Rapamycin Cytotoxic T Lymphocytes Tumor-Associated Macrophages Natural Killer Cells Dendritic Cells Myeloid-Derived Suppressor Cells Vascular Endothelial Growth Factor Endothelial Cells Cancer-Associated Fibroblasts Hypoxia-Inducible Factors Vascular Endothelial Growth Factor Receptor Epithelial-Mesenchymal Transition Endothelial-Mesenchymal Transition Tumor Endothelial Marker ATP-Binding Cassette Subfamily B Member 1 Tumor-Associated Endothelial Cells Regulatory T Cells Bone Marrow-Derived Dendritic Cells Circulating Tumor DNA Cell-Free DNA Copy Number Variations Cerebrospinal Fluid Breast Cancer Leptomeningeal Metastasis Pre-Metastatic Niche Chemokine (C-C Motif) Ligand 2 Transforming Growth Factor Beta Interleukin-10 Annexin A1 Antigen-Presenting Cells Immunogenic Cell Death Toll-Like Receptor Granulocyte-Macrophage Colony-Stimulating Factor Effector T Cells Forkhead Box O3 Programmed Cell Death Protein 1 Sterol Regulatory Element-Binding Proteins Programmed Cell Death Protein 4 Lin-28 Homolog B Monocarboxylate Transporters 1 and 4 Reactive Oxygen Species Indoleamine 2,3-Dioxygenase Arginase 2 Authors’ contributions HR, WZW, and YPL discussed and determined the theme together. XL, FJH and QW revised the images. SL and XDZ wrote the original draft. YQZ, XS, and SL revised the manuscript. All authors reviewed and approved the manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Shan Liu, Xingda Zhang, Wenzheng Wang and Xue Li contributed equally to this work. Contributor Information Yingpu Li, Email: liyingpu@hrbmu.edu.cn. Fangjie Hu, Email: 18846419361@163.com. He Ren, Email: renhe@hrbmu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement No datasets were generated or analysed during the current study.